<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.2" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">68719</article-id><article-id pub-id-type="doi">10.7554/eLife.68719</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Structural Biology and Molecular Biophysics</subject></subj-group></article-categories><title-group><article-title>Structural insights into hormone recognition by the human glucose-dependent insulinotropic polypeptide receptor</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-231787"><name><surname>Zhao</surname><given-names>Fenghui</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-231768"><name><surname>Zhang</surname><given-names>Chao</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-231769"><name><surname>Zhou</surname><given-names>Qingtong</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8124-3079</contrib-id><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-231770"><name><surname>Hang</surname><given-names>Kaini</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-231771"><name><surname>Zou</surname><given-names>Xinyu</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-231772"><name><surname>Chen</surname><given-names>Yan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-231773"><name><surname>Wu</surname><given-names>Fan</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-231774"><name><surname>Rao</surname><given-names>Qidi</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-150439"><name><surname>Dai</surname><given-names>Antao</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-231775"><name><surname>Yin</surname><given-names>Wanchao</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-231776"><name><surname>Shen</surname><given-names>Dan-Dan</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-231777"><name><surname>Zhang</surname><given-names>Yan</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-231778"><name><surname>Xia</surname><given-names>Tian</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-231779"><name><surname>Stevens</surname><given-names>Raymond C</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-185957"><name><surname>Xu</surname><given-names>H Eric</given-names></name><email>eric.xu@simm.ac.cn</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund9"/><xref ref-type="other" rid="fund10"/><xref ref-type="other" rid="fund11"/><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-150445"><name><surname>Yang</surname><given-names>Dehua</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3028-3243</contrib-id><email>dhyang@simm.ac.cn</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund7"/><xref ref-type="other" rid="fund13"/><xref ref-type="other" rid="fund16"/><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-231780"><name><surname>Zhao</surname><given-names>Lihua</given-names></name><email>zhaolihuawendy@simm.ac.cn</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund16"/><xref ref-type="other" rid="fund14"/><xref ref-type="other" rid="fund15"/><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-150438"><name><surname>Wang</surname><given-names>Ming-Wei</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6550-9017</contrib-id><email>mwwang@simm.ac.cn</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund8"/><xref ref-type="other" rid="fund12"/><xref ref-type="fn" rid="con18"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>School of Pharmacy, Fudan University</institution><addr-line><named-content content-type="city">Shanghai</named-content></addr-line><country>China</country></aff><aff id="aff2"><label>2</label><institution>The CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences</institution><addr-line><named-content content-type="city">Shanghai</named-content></addr-line><country>China</country></aff><aff id="aff3"><label>3</label><institution>School of Life Science and Technology, ShanghaiTech University</institution><addr-line><named-content content-type="city">Shanghai</named-content></addr-line><country>China</country></aff><aff id="aff4"><label>4</label><institution>University of Chinese Academy of Sciences</institution><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff><aff id="aff5"><label>5</label><institution>Department of Pharmacology, School of Basic Medical Sciences, Fudan University</institution><addr-line><named-content content-type="city">Shanghai</named-content></addr-line><country>China</country></aff><aff id="aff6"><label>6</label><institution>School of Artificial Intelligence and Automation, Huazhong University of Science and Technology</institution><addr-line><named-content content-type="city">Wuhan</named-content></addr-line><country>China</country></aff><aff id="aff7"><label>7</label><institution>The National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences</institution><addr-line><named-content content-type="city">Shanghai</named-content></addr-line><country>China</country></aff><aff id="aff8"><label>8</label><institution>Department of Biophysics and Department of Pathology of Sir Run Run Shaw Hospital, Zhejiang University School of Medicine</institution><addr-line><named-content content-type="city">Hangzhou</named-content></addr-line><country>China</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Drew</surname><given-names>David</given-names></name><role>Reviewing Editor</role><aff><institution>Stockholm University</institution><country>Sweden</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Dötsch</surname><given-names>Volker</given-names></name><role>Senior Editor</role><aff><institution>Goethe University</institution><country>Germany</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>13</day><month>07</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>10</volume><elocation-id>e68719</elocation-id><history><date date-type="received" iso-8601-date="2021-03-24"><day>24</day><month>03</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2021-07-06"><day>06</day><month>07</month><year>2021</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2021-03-19"><day>19</day><month>03</month><year>2021</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2021.03.18.436101"/></event></pub-history><permissions><copyright-statement>© 2021, Zhao et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Zhao et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-68719-v2.pdf"/><abstract><p>Glucose-dependent insulinotropic polypeptide (GIP) is a peptide hormone that exerts crucial metabolic functions by binding and activating its cognate receptor, GIPR. As an important therapeutic target, GIPR has been subjected to intensive structural studies without success. Here, we report the cryo-EM structure of the human GIPR in complex with GIP and a G<sub>s</sub> heterotrimer at a global resolution of 2.9 Å. GIP adopts a single straight helix with its N terminus dipped into the receptor transmembrane domain (TMD), while the C terminus is closely associated with the extracellular domain and extracellular loop 1. GIPR employs conserved residues in the lower half of the TMD pocket to recognize the common segments shared by GIP homologous peptides, while uses non-conserved residues in the upper half of the TMD pocket to interact with residues specific for GIP. These results provide a structural framework of hormone recognition and GIPR activation.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>glucose-dependent insulinotropic polypeptide receptor</kwd><kwd>cryo-electron microscopy</kwd><kwd>G protein-coupled receptor</kwd><kwd>ligand recognition</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>81872915</award-id><principal-award-recipient><name><surname>Wang</surname><given-names>Ming-Wei</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>32071203</award-id><principal-award-recipient><name><surname>Zhao</surname><given-names>Lihua</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>81773792</award-id><principal-award-recipient><name><surname>Yang</surname><given-names>Dehua</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>81973373</award-id><principal-award-recipient><name><surname>Yang</surname><given-names>Dehua</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>21704064</award-id><principal-award-recipient><name><surname>Zhou</surname><given-names>Qingtong</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution>National Science and Technology Major Project of China</institution></institution-wrap></funding-source><award-id>2018ZX09735-001</award-id><principal-award-recipient><name><surname>Wang</surname><given-names>Ming-Wei</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution>National Science and Technology Major Project of China</institution></institution-wrap></funding-source><award-id>2018ZX09711002-002-005</award-id><principal-award-recipient><name><surname>Yang</surname><given-names>Dehua</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution>National Key Basic Research Program of China</institution></institution-wrap></funding-source><award-id>2018YFA0507000</award-id><principal-award-recipient><name><surname>Wang</surname><given-names>Ming-Wei</given-names></name></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution>Ministry of Science and Technology of China</institution></institution-wrap></funding-source><award-id>2018YFA0507002</award-id><principal-award-recipient><name><surname>Xu</surname><given-names>H Eric</given-names></name></principal-award-recipient></award-group><award-group id="fund10"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003399</institution-id><institution>Shanghai Municipal Science and Technology Commission</institution></institution-wrap></funding-source><award-id>2019SHZDZX02</award-id><principal-award-recipient><name><surname>Xu</surname><given-names>H Eric</given-names></name></principal-award-recipient></award-group><award-group id="fund11"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002367</institution-id><institution>Chinese Academy of Sciences</institution></institution-wrap></funding-source><award-id>XDB37030103</award-id><principal-award-recipient><name><surname>Xu</surname><given-names>H Eric</given-names></name></principal-award-recipient></award-group><award-group id="fund12"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100012543</institution-id><institution>Shanghai Science and Technology Development Fund</institution></institution-wrap></funding-source><award-id>18430711500</award-id><principal-award-recipient><name><surname>Wang</surname><given-names>Ming-Wei</given-names></name></principal-award-recipient></award-group><award-group id="fund13"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004191</institution-id><institution>Novo Nordisk</institution></institution-wrap></funding-source><award-id>NNCAS-2017-1-CC</award-id><principal-award-recipient><name><surname>Yang</surname><given-names>Dehua</given-names></name></principal-award-recipient></award-group><award-group id="fund14"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100012543</institution-id><institution>Shanghai Science and Technology Development Fund</institution></institution-wrap></funding-source><award-id>18ZR1447800</award-id><principal-award-recipient><name><surname>Zhao</surname><given-names>Lihua</given-names></name></principal-award-recipient></award-group><award-group id="fund15"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004739</institution-id><institution>Youth Innovation Promotion Association of the Chinese Academy of Sciences</institution></institution-wrap></funding-source><award-id>2018325</award-id><principal-award-recipient><name><surname>Zhao</surname><given-names>Lihua</given-names></name></principal-award-recipient></award-group><award-group id="fund16"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002843</institution-id><institution>Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Yang</surname><given-names>Dehua</given-names></name><name><surname>Zhao</surname><given-names>Lihua</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>The structure provides key insights into hormone recognition and activation of the glucose-dependent insulinotropic polypeptide receptor.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Glucose-dependent insulinotropic polypeptide (GIP) is a 42-amino acid peptide hormone that plays crucial role in glucose regulation and fatty acid metabolism. In response to food intake, GIP is secreted by intestinal K cells to enhance insulin secretion and peripheral fatty acid uptake (<xref ref-type="bibr" rid="bib22">Kim et al., 2007</xref>), as well as a number of neuronal effects (<xref ref-type="bibr" rid="bib13">Faivre and Hölscher, 2013</xref>). The pleiotropic functions of GIP is mediated by its cognate receptor (GIPR), a member of class B1 G protein-coupled receptors (GPCRs) that also include glucagon receptor (GCGR) and glucagon-like peptide-1 receptor (GLP-1R). GIPR, together with GCGR and GLP-1R, forms the central endocrine network in regulating insulin sensitivity and energy homeostasis, and they are validated drug targets (<xref ref-type="bibr" rid="bib24">Lagerström and Schiöth, 2008</xref>; <xref ref-type="bibr" rid="bib14">Finan et al., 2016</xref>; <xref ref-type="bibr" rid="bib28">Longuet et al., 2008</xref>). Intensive efforts were made in drug discovery targeting these receptors (<xref ref-type="bibr" rid="bib43">Yang et al., 2021</xref>). A number of GLP-1R selective ligands have been developed successfully to treat type 2 diabetes and obesity. Encouragingly, peptide ligands that bind both GIPR and GLP-1R show better clinical efficacy than the GLP-1R agonist alone. As such, GIPR has emerged as a hot target pursued by pharmaceutical research community.</p><p>GIPR contains a large extracellular domain (ECD) and a 7-transmembrane domain (TMD). Both are involved in ligand recognition and receptor activation (<xref ref-type="bibr" rid="bib32">Parthier et al., 2009</xref>; <xref ref-type="bibr" rid="bib23">Koth et al., 2012</xref>; <xref ref-type="bibr" rid="bib42">Yang et al., 2015</xref>). Cryo-electron microscopy (cryo-EM) structures of GCGR and GLP-1R, as well as several other class B1 GPCRs have been solved, providing a general mechanism of two-domain model for peptide recognition and receptor activation. However, GIP displays an exquisite sequence specificity towards GIPR as it does not bind to other class B1 GPCRs. However, the efforts to understand the ligand selectivity by GIPR have been hampered by technical difficulties in expression and stabilization of the ligand-GIPR complexes for structural studies. We have overcome such challenges and determined a high-resolution (2.9 Å) structure of the human GIPR in complex with the stimulatory G protein (G<sub>s</sub>) using single-particle cryo-EM approach in conjunction with NanoBiT strategy (<xref ref-type="bibr" rid="bib11">Duan et al., 2020</xref>). Together with functional studies, our results demonstrate several unique structural features that distinguish GIPR from other members of the glucagon subfamily of class B1 GPCRs and provide an important template for rational design of GIPR agonists for therapeutic development.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Structure determination</title><p>To prepare a high-quality human GIPR–G<sub>s</sub> complex, we overcame several technical obstacles to enhance the expression level and protein stability by adding a double tag of maltose binding protein at the C terminus and a BRIL fusion protein at the N terminus (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>), as well as employing the NanoBiT tethering strategy (<xref ref-type="bibr" rid="bib11">Duan et al., 2020</xref>; <xref ref-type="bibr" rid="bib51">Zhou et al., 2020</xref>; <xref ref-type="bibr" rid="bib38">Sun et al., 2020</xref>; <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A,B</xref>). To solve the GIP<sub>1-42</sub>–GIPR–G<sub>s</sub> structure, we further introduced one mutation (T345F) to stabilize the assembly of complex (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C,D</xref>). This mutation does not affect the ligand binding or potency of GIP<sub>1-42</sub> in cAMP accumulation assay (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1G,H</xref>). Large-scale purification was followed and the GIP<sub>1-42</sub>–GIPR–G<sub>s</sub> complexes were collected by size-exclusion chromatography (SEC) for cryo-EM studies (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1E,F</xref>). The activity of the modified GIPR construct was confirmed by cAMP accumulation assay showing a response similar to that of the wild-type (WT; <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1G</xref>).</p><p>The GIP<sub>1-42</sub>–GIPR–G<sub>s</sub> complexes were imaged using a Titan Krios equipped with a Gatan K3 Summit direct electron detector (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>). 2D classification showed a clear secondary structure feature and random distribution of the particles. Different directions of the particles enabled a high-resolution cryo-EM map reconstruction (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2B</xref>). A total of 295,021 particles were selected after 3D refinement and polishing, leading to an overall resolution of 2.9 Å (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2C,D</xref> and <xref ref-type="table" rid="table1">Table 1</xref>).</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Cryo-EM data collection, refinement, and validation statistics.</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top">GIP–GIPR–G<sub>s</sub>–Nb35 complex</th><th valign="top"/></tr></thead><tbody><tr><td valign="top">Data collection and processing</td><td valign="top"/></tr><tr><td valign="top">Magnification</td><td valign="top">46,685</td></tr><tr><td valign="top">Voltage (kV)</td><td valign="top">300</td></tr><tr><td valign="top">Electron exposure (e<sup>–</sup>/Å<sup>2</sup>)</td><td valign="top">80</td></tr><tr><td valign="top">Defocus range (μm)</td><td valign="top">−1.2 to −2.2</td></tr><tr><td valign="top">Pixel size (Å)</td><td valign="top">1.071</td></tr><tr><td valign="top">Symmetry imposed</td><td valign="top">C1</td></tr><tr><td valign="top">Initial particle images (no.)</td><td valign="top">4,895,399</td></tr><tr><td valign="top">Final particle images (no.)</td><td valign="top">295,021</td></tr><tr><td valign="top">Map resolution (Å) <break/>FSC threshold</td><td valign="top">2.9 <break/>0.143</td></tr><tr><td valign="top">Map resolution range (Å)</td><td valign="top">2.7–5.0</td></tr><tr><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Refinement</td><td valign="top"/></tr><tr><td valign="top">Initial model used (PDB code)</td><td valign="top">PDB codes 6WPW and 2QKH</td></tr><tr><td valign="top">Model resolution (Å) <break/>FSC threshold</td><td valign="top">2.9 <break/>0.5</td></tr><tr><td valign="top">Model resolution range (Å)</td><td valign="top">2.7–5.0</td></tr><tr><td valign="top">Map sharpening B factor (Å<sup>2</sup>)</td><td valign="top">−86.3</td></tr><tr><td valign="top">Model composition <break/>Non-hydrogen atoms <break/>Protein residues <break/>Lipids</td><td valign="top"><break/>9409 <break/>1156 <break/>6</td></tr><tr><td valign="top">B factors (Å<sup>2</sup>) <break/>Protein <break/>Ligand <break/>Lipids</td><td valign="top"><break/>133 <break/>143 <break/>121</td></tr><tr><td valign="top">R.m.s. deviations <break/>Bond lengths (Å) <break/>Bond angles (Å)</td><td valign="top"><break/>0.005 <break/>1.036</td></tr><tr><td valign="top">Validation <break/>MolProbity score <break/>Clash score <break/>Poor rotamers (%)</td><td valign="top"><break/>1.21 <break/>4.23 <break/>0.00</td></tr><tr><td valign="top">Ramachandran plot <break/>Favored (%) <break/>Allowed (%) <break/>Disallowed (%)</td><td valign="top"><break/>98.15 <break/>1.85 <break/>0.00</td></tr></tbody></table></table-wrap></sec><sec id="s2-2"><title>Overall structure</title><p>Apart from the α-helical domain (AHD) of Gα<sub>s</sub> which is flexible in most cryo-EM GPCR–G protein complex structures, the bound GIP<sub>1-42</sub>, GIPR, and G<sub>s</sub> were well defined in the EM density maps (<xref ref-type="fig" rid="fig1">Figure 1</xref>, <xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref>). Except for the ECD, side chains of the majority of amino acid residues are well resolved in all protein components. The final model contains 30 GIP<sub>1-42</sub> residues, the Gαβγ subunits of G<sub>s</sub>, and the GIPR residues from Q30<sup>ECD</sup> to S415<sup>8.66b</sup> (class B GPCR numbering in superscript) (<xref ref-type="bibr" rid="bib40">Wootten et al., 2013</xref>), with six amino acid residues missing at helix 8. As a general feature in most reported class B1 GPCR–G<sub>s</sub> complex structures (<xref ref-type="bibr" rid="bib34">Qiao et al., 2020</xref>; <xref ref-type="bibr" rid="bib46">Zhang et al., 2017a</xref>; <xref ref-type="bibr" rid="bib50">Zhao et al., 2019</xref>; <xref ref-type="bibr" rid="bib29">Ma et al., 2020</xref>), the density of ECD is relatively poor owning to its intrinsic flexibility, which limited the accuracy in model building for the GIPR ECD region compared to other regions of the complex structure. Given a low resolution of the density map, the ECD structure is model based on the crystal structure of GIPR ECD (PDB code: 2QKH). Notable conformation difference from GCGR (<xref ref-type="bibr" rid="bib34">Qiao et al., 2020</xref>) or GLP-1R (<xref ref-type="bibr" rid="bib46">Zhang et al., 2017a</xref>) was observed in the extracellular loop 1 (ECL1).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Cryo-EM structure of the GIP<sub>1-42</sub>–GIPR–G<sub>s</sub> complex.</title><p>(<bold>A</bold>) Cut-through view of the cryo-EM density map that illustrates the GIP<sub>1-42</sub>–GIPR–G<sub>s</sub> complex and the disc-shaped micelle. The unsharpened cryo-EM density map at the 0.07 threshold shown as light gray surface indicates a micelle diameter of 11 nm. The colored cryo-EM density map is shown at the 0.16 threshold. (<bold>B</bold>) Model of the complex as a cartoon, with GIP<sub>1-42</sub> as helix in orange. The receptor is shown in light sky blue, Gα<sub>s</sub> in yellow, Gβ subunit in cyan, Gγ subunit in navy blue, and Nb35 in gray.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Effects of GIP<sub>1-42</sub>-mediated cAMP accumulation and binding affinity.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-68719-fig1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68719-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Purification and characterization of the GIP<sub>1-42</sub>–GIPR–G<sub>s</sub>–Nb35 complex.</title><p>(<bold>A</bold>) Human GIPR constructs used for structure determination. The signal peptide of the GIPR was replaced by the HA signal peptide (blue). A BRIL fusion protein was added at the N terminus of the receptor, followed by a TEV protease site between them. GIPR was truncated at R421, followed by a 15 amino acid linker (15AA, dark blue) and LgBiT (green). The C terminus was modified with a TEV protease site and an OMBP-MBP (light green) tag. The mutation site at T345 was highlighted in red. (<bold>B</bold>) Gβ1 constructs used for structure determination. Rat Gβ1 (orange) was attached to peptide 86 (orange) with a 15AA linker (dark blue) between them. (<bold>C</bold>) Size-exclusion chromatography results of the GIP<sub>1-42</sub>–GIPR(22-421)<bold>–</bold>G<sub>s</sub>–Nb35 (black line) and GIP<sub>1-42</sub>–GIPR(22-421)(T345F)–G<sub>s</sub>–Nb35 (red line) complexes on Superose 6 Increase 10/300GL. (<bold>D</bold>) SDS-PAGE of the GIP<sub>1-42</sub>–GIPR(22-421)<bold>–</bold>G<sub>s</sub>–Nb35 and GIP<sub>1-42</sub>–GIPR(22-421)(T345F)<bold>–</bold>G<sub>s</sub>–Nb35 complexes. (<bold>E</bold>) Size-exclusion chromatography results on Superose 6 Increase 10/300GL. (<bold>F</bold>) SDS–PAGE of the GIP<sub>1-42</sub>–GIPR–G<sub>s</sub>–Nb35 complex. (<bold>G</bold>) cAMP responses following GIP<sub>1-42</sub> stimulation in HEK 293T cells transfected with wild-type (WT, HA-Flag-3GSA-GIPR(22-466)) or truncated GIPR constructs (HA-Flag-3GSA-BRIL-TEV-2GSA-GIPR(22-421)T345F-15AA-LgBiT-TEV-2MBP). Signals were normalized to the maximum response of WT and dose–response curves were analyzed using a three-parameter logistic equation. (<bold>H</bold>) Binding of GIP<sub>1-42</sub> to the full length (residues 22-466) or truncated (residues 22-421) GIPR in CHO-K1 cells in competition with <sup>[125I]</sup>-GIP<sub>1-42</sub>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68719-fig1-figsupp1-v2.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Cryo-EM analysis of the GIP<sub>1-42</sub>–GIPR–G<sub>s</sub> complex.</title><p>(<bold>A</bold>) Representative cryo-EM micrograph (scale bar: 50 nm) and two-dimensional class averages (scale bar: 5 nm). (<bold>B</bold>) Flow chart of cryo-EM data processing. Details are described in Materials and methods. (<bold>C</bold>) Local resolution distribution map of the GIP<sub>1-42</sub>–GIPR–G<sub>s</sub> complex. (<bold>D</bold>) Gold-standard Fourier shell correlation (FSC) curves of overall refined receptor.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68719-fig1-figsupp2-v2.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 3.</label><caption><title>Atomic resolution model of the GIP<sub>1-42</sub>–GIPR–G<sub>s</sub> complex in the cryo-EM density map.</title><p>EM density map and model are shown for all seven transmembrane α-helices (<bold>A</bold>), ECD, helix eight, and all extracellular loops of GIPR, the α5-helix of the Gα<sub>s</sub> Ras-like domain and GIP<sub>1-42</sub> (<bold>B</bold>). Insert in (<bold>A</bold>) is the close-up of the density of F345<sup>6.44b</sup>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68719-fig1-figsupp3-v2.tif"/></fig></fig-group><p>Similar to other class B1 GPCR–G<sub>s</sub> complexes, the TM6 of GIPR shows a sharp kink in the middle and TM7 displays an outward movement. Like parathyroid hormone receptor-1 (PTH1R)–G<sub>s</sub> and corticotropin-releasing factor receptor type 1 (CRF1R)–G<sub>s</sub> cryo-EM structures (<xref ref-type="bibr" rid="bib50">Zhao et al., 2019</xref>; <xref ref-type="bibr" rid="bib29">Ma et al., 2020</xref>), the TMD of GIPR is surrounded by annular detergent micelle, with a diameter of 12 nm thereby mimicking the lipid bilayer morphology (<xref ref-type="fig" rid="fig1">Figure 1</xref>). In addition, we also observed several cholesterols molecules in the cryo-EM map.</p></sec><sec id="s2-3"><title>Ligand recognition</title><p>In the complex, GIP adopts a single continuous helix that penetrates into the TMD core through its N-terminal half (residues 1–15), while the C-terminal half (residues 16–30) is recognized by the ECD and ECL1 (<xref ref-type="fig" rid="fig2">Figure 2A–C</xref>). Y1<sup>P</sup> (P indicates that the residue belongs to the peptide ligand) of GIP points to TMs 2–3, forms hydrogen bonds with R190<sup>2.67b</sup> and Q224<sup>3.37b</sup>, and makes hydrophobic contacts with V227<sup>3.40b</sup> and W296<sup>5.36b</sup>. This observation received support of the mutagenesis study, where mutant W296A decreased the potency of GIP-induced cAMP signaling by 50-fold (<xref ref-type="fig" rid="fig2">Figure 2D</xref>), and the reductions in mutants R190A and Q224A were 71- and 5-fold, respectively, as reported in a previous report (<xref ref-type="bibr" rid="bib44">Yaqub et al., 2010</xref>). N-terminal truncation of either Y1<sup>P</sup> or both Y1<sup>P</sup> and A2<sup>P</sup> led to reduced efficacy or loss of activity (<xref ref-type="bibr" rid="bib21">Kerr et al., 2011</xref>; <xref ref-type="bibr" rid="bib15">Gabe et al., 2020</xref>), highlighting a crucial role of Y1<sup>P</sup>. E3<sup>P</sup>, D9<sup>P</sup>, and D15<sup>P</sup> are three negatively charged residues in the N-terminal half of GIP and form salt bridges with R183<sup>2.60b</sup>, R370<sup>7.35b</sup>, and R289<sup>ECL2</sup>, respectively. Removal of these salt bridges by alanine substitution at either R183<sup>2.60b</sup> (<xref ref-type="bibr" rid="bib44">Yaqub et al., 2010</xref>) or R370<sup>7.35b</sup> (<xref ref-type="fig" rid="fig2">Figure 2D</xref>) greatly reduced GIP potency (by 76- and 55-fold, respectively), whereas the effect on mutant R289A was mild (6-fold, <xref ref-type="fig" rid="fig2">Figure 2D</xref>). Polar interactions also occurred between S8<sup>P</sup> and N290<sup>ECL2</sup> as well as Y10<sup>P</sup> and Q138<sup>1.40b</sup>. The GIP–TMD interface was further stabilized by a complementary nonpolar network involving TM1 (L134<sup>1.36b</sup>, L137<sup>1.39b</sup>, and Y141<sup>1.43b</sup>) and TM7 (L374<sup>7.39b</sup> and I378<sup>7.43b</sup>) via A2<sup>P</sup>, F6<sup>P</sup>, and Y10<sup>P</sup> of GIP (<xref ref-type="fig" rid="fig2">Figure 2C</xref>), in line with decreased ligand potencies observed in Y141A (by 103-fold), L374A (by 41-fold), and I378A (by 8-fold) mutants (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). These mutants also caused significant potency decreases in GIP<sub>1-42</sub>-induced β-arrestin2 recruitment (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Molecular recognition of GIP by GIPR.</title><p>(<bold>A</bold>) The binding mode of GIP (orange) with GIPR (light sky blue), showing that the N-terminal half of GIP penetrates into a pocket formed by all TM helices except TM4, ECL2, and ECL3, whereas the C-terminal half is recognized by ECD, ECL1, and TM1. (<bold>B, C</bold>) Close-up views of the interactions between GIP and GIPR. The residues and side chains that could not be modelled in the ECD are colored in red. (<bold>D</bold>) Signaling profiles of GIPR mutants. cAMP accumulation in wild-type (WT) and single-point mutated GIPR expressing in HEK 293T cells. Signals were normalized to the maximum response of the WT and dose–response curves were analyzed using a three-parameter logistic equation. All data were generated and graphed as means ± S.E.M. of at least three independent experiments, conducted in quadruplicate. Δ, truncated residues.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Effects of residue mutation in the ligand-binding pocket on GIP<sub>1-42</sub>-induced cAMP accumulation, cell surface expression, and binding affinity.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-68719-fig2-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68719-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Effects of residue mutation in the ligand-binding pocket on GIP<sub>1-42</sub>-induced β-arrestin2 recruitment.</title><p>GIP<sub>1-42</sub> induced β-arrestin2 recruitment. HEK 293 T cells were transiently co-transfected with GIPR-Rluc8 and Venus-β-arrestin2 (β-arr2). Data presented are AUC of BRET signals measured for 10 min post-stimulation. For quantification of concentration-responses, data were corrected for the vehicle control and then normalized to the maximal response of wild-type (WT) GIPR. Data were fitted to non-linear regression three-parameter logistic curves. Δ, truncated residues.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68719-fig2-figsupp1-v2.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Conformational changes upon GIPR activation.</title><p>Comparison of active GIPR with inactive, agonist-bound, and both agonist-bound and G protein-coupled active GCGR (<xref ref-type="bibr" rid="bib49">Zhang et al., 2020</xref>). G proteins are omitted for clarity.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68719-fig2-figsupp2-v2.tif"/></fig></fig-group><p>The C-terminal half of GIP was clasped by the GIPR ECD, closely resembling the crystal structure of GIP–GIPR ECD (PDB code: 2QKH) (<xref ref-type="bibr" rid="bib31">Parthier et al., 2007</xref>). Consistent with the interaction patterns observed in other class B1 GPCRs (<xref ref-type="bibr" rid="bib31">Parthier et al., 2007</xref>), the hydrophobic residues (F22<sup>P</sup>, V23<sup>P</sup>, L26<sup>P</sup>, and L27<sup>P</sup>) in the C-terminal half of GIP occupy a complementary binding groove of the GIPR ECD, consisting of a series of hydrophobic residues (L35, Y36, W39, M67, Y68, Y87, L88, P89, and W90). Alanine substitutions in W39, D66, and Y68 significantly reduced the potency of GIP (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). Besides, several polar contacts including H18<sup>P</sup>-Y36 and Q20<sup>P</sup>-N124 were observed. Notably, the cryo-EM map suggests that the ECL1 stands upwards to approach the N-terminal α-helix of ECD and forms hydrogen bonds with the side chain of Y36 (<xref ref-type="fig" rid="fig2">Figure 2A,B</xref>), resulting in a close contact between TMD and ECD for GIP-bound GIPR (interface area = 571 Å<sup>2</sup>), significantly larger than that of GLP-1-bound GLP-1R (362 Å<sup>2</sup>), reinforcing the importance of ECD in GIP recognition.</p></sec><sec id="s2-4"><title>Receptor activation</title><p>GIPR shares ~50% sequence similarity with GCGR, especially in the TMD region (75%); thus, GCGR structures published previously provide a good template for the present study (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>; <xref ref-type="bibr" rid="bib34">Qiao et al., 2020</xref>; <xref ref-type="bibr" rid="bib18">Hilger et al., 2020</xref>; <xref ref-type="bibr" rid="bib20">Jazayeri et al., 2016</xref>; <xref ref-type="bibr" rid="bib48">Zhang et al., 2018</xref>; <xref ref-type="bibr" rid="bib6">Chang et al., 2020</xref>). It was found the TMD of activated GIPR exhibits a conformation similar to that of GCGR activated by glucagon or ZP3780 (Cα RMSD = 1.2 and 0.7 Å, respectively) (<xref ref-type="bibr" rid="bib34">Qiao et al., 2020</xref>; <xref ref-type="bibr" rid="bib18">Hilger et al., 2020</xref>) and distinct from that of GCGR bound by the negative allosteric modulator NNC0640 or partial agonist NNC1702 (Cα RMSD = 4.0 and 3.9 Å, respectively) (<xref ref-type="bibr" rid="bib47">Zhang et al., 2017b</xref>). Facilitated by Gly<sup>7.50b</sup> located in the middle of TM7, the extracellular half of TM7 bends towards TM6 by 8.0 Å (measured by Cα atom of Gly<sup>7.32b</sup>) (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>). This feature and the outward movement of ECL3 expanded the ligand binding pocket. Meanwhile, the extracellular tip of TM1 was extended by one turn and moved inward by 8.0 Å (measured by Cα atom of the residues at 1.30b) (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>). Together with the raised ECL1, these conformational changes stabilized ligand binding.</p><p>In the intracellular side, the sharp kink in the middle of TM6 led to an outward movement of its intracellular portion measured by Cα atom of R336<sup>6.35b</sup> (18.9 Å, similar to that of other G<sub>s</sub>-coupled class B1 receptors). This was accompanied by the movement of the intracellular tip of TM5 toward TM6 by 7.6 Å (measured by Cα atom of the residues at 5.67b), thereby creating an intracellular cavity for G protein coupling (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>).</p></sec><sec id="s2-5"><title>G protein coupling</title><p>In our model, G<sub>s</sub> protein is anchored by the α5 helix of Gα<sub>s</sub> (GαH5), thereby fitting to the cytoplasmic cavity formed by TMs 3, 5, and 6, intracellular loops (ICLs) 1–2 and H8 (<xref ref-type="fig" rid="fig3">Figure 3</xref>). In general, the GIPR–G<sub>s</sub> complex shows a similar receptor–G protein interface as other reported class B1 receptor structures such as GLP-1R (<xref ref-type="bibr" rid="bib49">Zhang et al., 2020</xref>), GLP-2R (glucagon-like peptide-2 receptor) (<xref ref-type="bibr" rid="bib38">Sun et al., 2020</xref>), GCGR (<xref ref-type="bibr" rid="bib34">Qiao et al., 2020</xref>), PTH1R (<xref ref-type="bibr" rid="bib50">Zhao et al., 2019</xref>), SCTR (secretin receptor) (<xref ref-type="bibr" rid="bib10">Dong et al., 2020</xref>), and GHRHR (growth hormone-releasing hormone receptor) (<xref ref-type="bibr" rid="bib51">Zhou et al., 2020</xref>), suggesting a common G protein signaling mechanism (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). The hydrophobic residues at the C-terminal of GαH5 (L388<sup>GαH5</sup>, Y391<sup>GαH5</sup>, L393<sup>GαH5</sup>, and L394<sup>GαH5</sup>) insert into a small hydrophobic pocket formed by Y240<sup>3.53b</sup>, L241<sup>3.54b</sup>, L244<sup>3.57b</sup>, L245<sup>3.58b</sup>, I317<sup>5.58b</sup>, I320<sup>5.60b</sup>, L321<sup>5.61b</sup>, and L325<sup>5.65b</sup> (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). The side chain of R338<sup>6.37b</sup> points to Gα<sub>s</sub> and makes one hydrogen bond with L394<sup>GαH5</sup>. Of note is that the interaction between R380<sup>GαH5</sup> and ICL2 results in five hydrogen bonds with the backbone atoms of L245<sup>3.58b</sup>, V246<sup>3.59b</sup>, L247<sup>3.60b</sup>, and V248<sup>ICL2</sup>, significantly more than that observed in GLP-1R, SCTR, or GCGR (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). The polar residues in ICL2 (S251<sup>ICL2</sup> and E253<sup>ICL2</sup>) produce two hydrogen bonds with K34 and Q35 of Gα<sub>s</sub>, while H8 forms several hydrogen bonds with ICL1, then contacts with Gβ (E398<sup>8.49b</sup>-R164<sup>ICL1</sup>-D312<sup>Gβ</sup>, E402<sup>8.53b</sup>-R164<sup>ICL1</sup>-D312<sup>Gβ</sup>) (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). Together, these specific interactions contribute to the G<sub>s</sub> coupling specificity of GIPR.</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>G protein coupling of GIPR.</title><p>(<bold>A</bold>) Comparison of G protein coupling among GIPR, GLP-1R (<xref ref-type="bibr" rid="bib49">Zhang et al., 2020</xref>), GCGR (<xref ref-type="bibr" rid="bib34">Qiao et al., 2020</xref>), and SCTR (<xref ref-type="bibr" rid="bib10">Dong et al., 2020</xref>). The Gα<sub>s</sub> α5-helix of the Gα<sub>s</sub> Ras-like domain inserts into an intracellular crevice of GIPR TMD. (<bold>B</bold>) Interaction between GIPR and the C terminus of Gα<sub>s</sub>. (<bold>C</bold>) Polar interactions between ICL2 and Gα<sub>s</sub>. (<bold>D</bold>) Polar interactions between H8 and ICL1 of the GIPR and Gβ. The GIP<sub>1-42</sub>–GIPR–Gα<sub>s</sub> structure is colored light sky blue (GIPR), gold (Gα<sub>s</sub>), and cyan (Gβ). Residues involved in interactions are shown as sticks. Polar interactions are shown as black dashed lines.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68719-fig3-v2.tif"/></fig></sec><sec id="s2-6"><title>Ligand specificity</title><p>GIP, GLP-1, and glucagon are three important metabolic hormones exerting distinct functions in glucose homeostasis, in spite of high degrees of sequence similarity. Superimposing the TMD of GIP-bound GIPR with that of GLP-1-bound GLP-1R (<xref ref-type="bibr" rid="bib49">Zhang et al., 2020</xref>) or glucagon-bound GCGR (<xref ref-type="bibr" rid="bib34">Qiao et al., 2020</xref>) displays a similar ligand-binding pocket and the three peptides all adopt a single continuous helix, with the N terminus penetrating to the TMD core to the same depth, while the C terminus anchors the ECD and ECL1 in a receptor-specific manner (<xref ref-type="fig" rid="fig4">Figure 4</xref>). Notably, the ECL1 of GIPR stands upwards in line with TMs 2 and 3 and moves towards the TMD core by 5~7 Å. Such a movement, together with a α-helical extension in TM1 by six residues, allows GIP to shift to TM1 by 2.7 and 3.3 Å (measured by Cα atom of L27<sup>P</sup>) relative to GLP-1 (<xref ref-type="bibr" rid="bib49">Zhang et al., 2020</xref>) and glucagon (<xref ref-type="bibr" rid="bib34">Qiao et al., 2020</xref>), respectively (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Ligand specificity among GIPR, GLP-1R, and GCGR.</title><p>(<bold>A</bold>) Comparison of the overall structures of GIP<sub>1-42</sub>–GIPR–G<sub>s</sub>, GLP-1–GLP-1R–G<sub>s</sub> (<xref ref-type="bibr" rid="bib49">Zhang et al., 2020</xref>) and glucagon–GCGR–G<sub>s</sub> complexes (<xref ref-type="bibr" rid="bib34">Qiao et al., 2020</xref>). G proteins are omitted for clarity. (<bold>B–D</bold>) Close-up views of the interaction between TMD and peptide. Based on sequence similarity, the peptides are divided into four segments: N terminus (residues 1–3, <bold>B</bold>), segment 2 (residues 4–11, <bold>C</bold>), segment 3 (residues 12–20, <bold>D</bold>), and the C terminus (residues 21 to the end, <bold>E–G</bold>), where segments 2 and 4 are highly conserved among GIP, GLP-1, and glucagon. Residues are numbered based on GIP for peptides, and labeled with class B GPCR numbering in superscript for receptors (<xref ref-type="bibr" rid="bib40">Wootten et al., 2013</xref>). (<bold>E–G</bold>) Close-up views of the interface between GIPR ECD and GIP C terminus (<bold>E</bold>), between GLP-1R and GLP-1 C terminus (<bold>F</bold>), and between GCGR and glucagon C terminus (<bold>G</bold>). The ECD is shown in surface representation and colored from dodger blue for the most hydrophilic region, to white, to orange red for the most hydrophobic region. (<bold>H</bold>) Comparison of peptide recognition modes for three receptors, described by fingerprint strings encoding different interaction types of the surrounding residues in each receptor. Peptide residue numbers on the top are shown based on GIP. The ligand-binding pocket residues that are identical or similar across three receptors are highlighted in dark gray and light gray, respectively. Color codes are listed on the bottom.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68719-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Structural comparison of ECL1 conformations among GIPR, GLP-1R and GCGR.</title><p>The ECL1 conformation of GIP-bound GIPR is compared with that of GLP-1-bound GLP-1R (PDB code: 6X18) (<xref ref-type="bibr" rid="bib49">Zhang et al., 2020</xref>) and glucagon-bound GCGR (PDB code: 6LMK) (<xref ref-type="bibr" rid="bib49">Zhang et al., 2020</xref>). All structures are superimposed on the GIP-bound GIPR using the Cα carbons of the residues in the TM2–3–4. Receptor ECD and G protein are omitted for clarity.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68719-fig4-figsupp1-v2.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Molecular dynamics (MD) simulations of GIPR in complex with GLP-1 and glucagon.</title><p>(<bold>A</bold>) Left, comparison of peptide binding between simulation snapshots of GLP-1–GIPR and the cryo-EM structure of GIP–GIPR–G<sub>s</sub> complex. ECD and G protein are omitted for clarity. Right top, extracellular view of the interaction between peptide and TMD. Right bottom, the buried surface area between GLP-1 and GIPR. (<bold>B</bold>) Left, comparison of peptide binding between simulation snapshots of glucagon–GIPR and the cryo-EM structure of GIP–GIPR–G<sub>s</sub> complex. ECD and G protein are omitted for clarity. Right top, extracellular view of the interaction between peptide and TMD. Right bottom, the buried surface area between glucagon and GIPR. Interface areas were calculated using freeSASA (<xref ref-type="bibr" rid="bib49">Zhang et al., 2020</xref>).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68719-fig4-figsupp2-v2.tif"/></fig><fig id="fig4s3" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 3.</label><caption><title>Comparison of the cryo-EM structure of GIPR with other class B1 receptors.</title><p>(<bold>A</bold>) The glucagon subfamily of GPCRs (<xref ref-type="bibr" rid="bib51">Zhou et al., 2020</xref>; <xref ref-type="bibr" rid="bib38">Sun et al., 2020</xref>; <xref ref-type="bibr" rid="bib34">Qiao et al., 2020</xref>; <xref ref-type="bibr" rid="bib46">Zhang et al., 2017a</xref>; <xref ref-type="bibr" rid="bib10">Dong et al., 2020</xref>); (<bold>B</bold>) calcitonin subfamily (<xref ref-type="bibr" rid="bib25">Liang et al., 2018a</xref>); (<bold>C</bold>) corticotropin-releasing factor (CRF) subfamily (<xref ref-type="bibr" rid="bib29">Ma et al., 2020</xref>; <xref ref-type="bibr" rid="bib27">Liang et al., 2020</xref>); (<bold>D</bold>) pituitary adenylate-cyclase-activating peptide (PACAP) and vasoactive intestinal polypeptide (VIP) receptor subfamily (<xref ref-type="bibr" rid="bib11">Duan et al., 2020</xref>; <xref ref-type="bibr" rid="bib27">Liang et al., 2020</xref>; <xref ref-type="bibr" rid="bib39">Wang et al., 2020</xref>); (<bold>E</bold>) parathyroid hormone subfamily (<xref ref-type="bibr" rid="bib50">Zhao et al., 2019</xref>).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68719-fig4-figsupp3-v2.tif"/></fig><fig id="fig4s4" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 4.</label><caption><title>GIP<sub>1-42</sub>, GLP-1<sub>7-36</sub>, or glucagon-elicited cAMP accumulation was measured in HEK 293T cells expressing GIPR, GLP-1R, or GCGR, respectively.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68719-fig4-figsupp4-v2.tif"/></fig></fig-group><p>Based on the sequence similarity, the three peptides can be divided into four segments: two common segments (residues 4–11 and 21–30 in GIP) and two unique segments (residues 1–3 and 12–20 in GIP) (<xref ref-type="fig" rid="fig4">Figure 4H</xref>). The N terminus (residues 1–3) makes massive contacts with the conserved central polar network of class B1 GPCRs including one hydrogen bond with Q<sup>3.37b</sup> stabilized by the hydrophobic residue at 3.40b; one hydrogen bond with Y<sup>1.47b</sup> made by the third peptide residue (<xref ref-type="fig" rid="fig4">Figure 4B,H</xref>); residues 4–11 interact with salt bridges of R<sup>7.35b</sup>, pi-stacking of Y<sup>1.43b</sup>, hydrophobic L<sup>2.71b</sup>, W<sup>5.36b</sup>, and L<sup>7.39b</sup>, as well as several hydrogen bonds in ECL2 (<xref ref-type="fig" rid="fig4">Figure 4C,H</xref>); residues 12–20 are divergent and mainly interact with ECLs 1–2 and TMs 1–2 (<xref ref-type="fig" rid="fig4">Figure 4D,H</xref>).</p><p>To accommodate varying lengths of side chains at A<sup>13P</sup>/Y/Y, I<sup>17P</sup>/Q/R, Q<sup>19P</sup>/A/A, and Q<sup>20P</sup>/K/Q, both TM1 and ECL1 adjusted their conformations to avoid clashes (<xref ref-type="fig" rid="fig4">Figure 4D,</xref> <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). For example, ECL1 of GLP-1R is more distant from GLP-1 than that of GIPR from GIP, whereas repulsion of the side chain of R<sup>18P</sup> was seen between GCGR and glucagon. Therefore, receptor-specific interaction may reside in this region, which precludes the binding of GLP-1 or glucagon to GIPR revealed by MD simulations (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>). As far as C terminus is concerned, all three peptides form extensive hydrophobic contacts with the ECD, resulting from the hydrophobic composition of amino acids in both sides (<xref ref-type="fig" rid="fig4">Figure 4E–H</xref>). It appears that GIPR, GLP-1R, and GCGR employ conserved residues to recognize the common segments of their endogenous peptides and use non-conserved residues to make specific interaction that govern the ligand selectivity.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>As one of the incretin hormones, GIP modulates glucose metabolism by stimulating the β-cells to release insulin (<xref ref-type="bibr" rid="bib35">Seino et al., 2010</xref>). Unlike GLP-1, it does not suppress gastric emptying and appetite, while exerting opposite actions on pancreatic α-cells as well as adipocytes leading to glucagon secretion and lipogenesis (<xref ref-type="bibr" rid="bib35">Seino et al., 2010</xref>). Coupled with reduced sensitivity in type 2 diabetic patients, development of GIPR-based therapeutics met little success (<xref ref-type="bibr" rid="bib8">Coskun et al., 2018</xref>).</p><p>Comparison of the full-length structures of six glucagon subfamily of GPCRs demonstrates that bound peptides (GLP-1, exendin-P5, glucagon, ZP3780, secretin, GHRH, GLP-2, and GIP) all adopt a single straight helix with their N terminus inserted into the TMD core, while the C-terminal is recognized by the ECD (<xref ref-type="bibr" rid="bib51">Zhou et al., 2020</xref>; <xref ref-type="bibr" rid="bib38">Sun et al., 2020</xref>; <xref ref-type="bibr" rid="bib34">Qiao et al., 2020</xref>; <xref ref-type="bibr" rid="bib46">Zhang et al., 2017a</xref>; <xref ref-type="bibr" rid="bib10">Dong et al., 2020</xref>). For parathyroid hormone subfamily of GPCRs, the long-acting PTH analog (LA-PTH) predominantly exhibits an extended helix with its N terminus inserted deeply into the TMD, where the peptide C terminus may bend occasionally (<xref ref-type="bibr" rid="bib50">Zhao et al., 2019</xref>). In the case of CRF subfamily of GPCRs, the N terminus (first seven residues) of urocortin 1 (UCN1) and CRF1 present an extended loop conformation, and its C-terminal residues (8–40) adopt a single extended helix (<xref ref-type="bibr" rid="bib29">Ma et al., 2020</xref>; <xref ref-type="bibr" rid="bib27">Liang et al., 2020</xref>). As far as calcitonin subfamily of GPCRs is concerned, calcitonin gene-related peptide (CGRP) has an unstructured loop in both N- and C-terminal regions (<xref ref-type="bibr" rid="bib25">Liang et al., 2018a</xref>). Looking at pituitary adenylate-cyclase-activating peptide (PACAP) and vasoactive intestinal polypeptide (VIP) receptor subfamily, PACAP displays an extended α-helix, while maxadilan, a natural PAC1R agonist (61-amino acid long), forms the N- and C-terminal helices that are linked as a loop (<xref ref-type="bibr" rid="bib11">Duan et al., 2020</xref>; <xref ref-type="bibr" rid="bib27">Liang et al., 2020</xref>; <xref ref-type="bibr" rid="bib39">Wang et al., 2020</xref>). These observations highlight diversified peptide binding modes among class B1 GPCRs (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3</xref>).</p><p>Species differences in class B1 receptor responsiveness are diversified and receptor specific, which is tolerable for some receptors such as GLP-1R and GCGR, but leads to concerns for others like GIPR and parathyroid hormone receptor-2 (PTH2R) (<xref ref-type="bibr" rid="bib37">Sparre-Ulrich et al., 2016</xref>; <xref ref-type="bibr" rid="bib19">Hoare et al., 1999</xref>). Interestingly, the sequence identities between human and mouse at both ligand and receptor levels are more conserved between GLP-1 and GLP-1R (100% and 93%) than that between GIP and GIPR (92% and 81%) (<xref ref-type="bibr" rid="bib37">Sparre-Ulrich et al., 2016</xref>). Such a divergence is not caused by changes in peptide potency, but resides in the biological property of either GIP or the receptor (<xref ref-type="bibr" rid="bib37">Sparre-Ulrich et al., 2016</xref>; <xref ref-type="bibr" rid="bib4">Bailey, 2020</xref>). However, it may affect GIP-related pharmacology markedly (<xref ref-type="bibr" rid="bib37">Sparre-Ulrich et al., 2016</xref>). Indeed, a previous study found that human GIP is a comparatively weak partial agonist in rodent models (<xref ref-type="bibr" rid="bib37">Sparre-Ulrich et al., 2016</xref>). Human (Pro3)GIP is a full agonist with identical maximum response as human GIP, whereas both rat and mouse (Pro3)GIPs are partial agonists (<xref ref-type="bibr" rid="bib37">Sparre-Ulrich et al., 2016</xref>; <xref ref-type="bibr" rid="bib4">Bailey, 2020</xref>). Of note is that among rat, mouse, and human GIPs, the only residue change (from His to Arg) occurs at the 18th position (<xref ref-type="bibr" rid="bib37">Sparre-Ulrich et al., 2016</xref>). From a structural biology perspective, the variation in the sequences of both GIP (H<sup>18P</sup>/R/R for human, rat, and mouse) and GIPR, and the consequent alterations in either peptide-binding or G protein-coupling may offer an explanation. Nonetheless, it may also complicate knowledge transfer from rodents to humans for clinical development of GIPR-based therapeutics.</p><p>The interactions between the three receptors (GIPR, GLP-1R, and GCGR) and their endogenous peptides transduce precise cellular signals responsible for glucose control. While GIP<sub>1-42</sub>, GLP-1, and glucagon each binds to the cognate receptor with high affinity (pIC<sub>50</sub> = 8.07, 8.25 and 7.31, respectively), glucagon also cross-reacts with GLP-1R with a pIC<sub>50</sub> value of 6.19 (<xref ref-type="bibr" rid="bib45">Yuliantie et al., 2020</xref>; <xref ref-type="bibr" rid="bib9">Darbalaei et al., 2020</xref>). This property is consistent with their behavior in inducing cAMP responses: GIP<sub>1-42</sub> and GLP-1 specifically activate GIPR and GLP-1R, respectively, whereas glucagon can elicit cAMP accumulation mediated by both GCGR and GLP-1R (EC<sub>50</sub> = 1.14 nM; <xref ref-type="fig" rid="fig4s4">Figure 4—figure supplement 4</xref>), highlighting the complexity of their interactive functionalities. Our studies show that the recognition pattern among these three peptide–receptor pairs is instituted by a common and closely related mechanism where the extracellular portion of the receptor mainly binds to a cognate ligand, while the TMD activates a cascade of signaling events. The upper half of the TMD pocket composed of the top parts of ECL1, TM1, and TM2 interacts with unique residues in the peptide through flexible movement of ECL1 and complementary shape formation by TM1 and TM2, thereby conferring selectively and discriminating unrelated ligands. The lower half of the TMD pocket composed of TMs 3, 6, and 7 displays conserved sequences for recognition of common residues in the peptide. Its key function is to converge external signal into the cytoplasm and executes transduction with high efficiency. This mechanistic design reflects evolutionary advantages because multiple polypeptides could be accurately recognized via different sequences in the upper half of the TMD pocket.</p><p>Finally, GIPR, combined with GLP-1R and GCGR, have been intensively studied as targets of dual- or tri- agonists (<xref ref-type="bibr" rid="bib36">Skow et al., 2016</xref>; <xref ref-type="bibr" rid="bib2">Alexiadou et al., 2019</xref>). Combined activation of GLP-1R and GIPR by dual agonists would provide synergistic and improved effects in glycemic and body weight control (<xref ref-type="bibr" rid="bib5">Bastin and Andreelli, 2019</xref>). The GLP-1R/GIPR dual-agonists LY3298176 (developed by Eli Lilly) and NN9709 (developed by Novo Nordisk/Marcadia) as well as GLP-1R/GCGR/GIPR tri-agonist HM15211 (developed by Hamni Pharmaceuticals) are undergoing phase II or III clinical trials (<xref ref-type="bibr" rid="bib43">Yang et al., 2021</xref>). The detailed structural information on GIPR reported here will certainly be of value to better understand the mode of actions of these therapeutic peptides.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th>Reagent type (species) or resource</th><th>Designation</th><th>Source or reference</th><th>Identifiers</th><th>Additional information</th></tr></thead><tbody><tr><td valign="top">Gene</td><td valign="top">GIPR_human</td><td valign="top">NCBI</td><td valign="top">NM_000164.4</td><td valign="top"/></tr><tr><td valign="top">Strain, strain background(<italic>Escherichia coli</italic>)</td><td valign="top">BL21 (DE3)</td><td valign="top">TIANGEN</td><td valign="top">Cat # CB105</td><td valign="top"/></tr><tr><td valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td valign="top">HEK 293T</td><td valign="top">ATCC</td><td valign="top">Cat # CRL-3216</td><td valign="top"/></tr><tr><td valign="top">Cell line (hamster)</td><td valign="top">CHO-K1</td><td valign="top">ATCC</td><td valign="top">Cat # CCL-61</td><td valign="top"/></tr><tr><td valign="top">Cell line (insect)</td><td valign="top"><italic>Sf</italic>9</td><td valign="top">Invitrogen</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Cell line (insect)</td><td valign="top">High-Five insect cells</td><td valign="top">ThermoFisher Scientific</td><td valign="top">Cat # B85502</td><td valign="top"/></tr><tr><td valign="top">Recombinant <break/>DNA reagent</td><td valign="top">pFastBac-HA-BRIL-TEV-2GSA-GIPR(22-421)T345F-15AA-LgBiT-TEV-OMBP-MBP</td><td valign="top">This paper</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant <break/>DNA reagent</td><td valign="top">pFastBac-HA-BRIL-TEV-2GSA-GIPR(22-421)−15AA-LgBiT-TEV-OMBP-MBP</td><td valign="top">This paper</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant <break/>DNA reagent</td><td valign="top">pFastBac-DNGα<sub>s</sub></td><td valign="top">This paper</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant <break/>DNA reagent</td><td valign="top">pFastBac-Gβ1-peptide 86</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/s41422-020-00442-0">https://doi.org/10.1038/s41422-020-00442-0</ext-link></td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant <break/>DNA reagent</td><td valign="top">pFastBac-Gγ2</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/s41422-020-00442-0">https://doi.org/10.1038/s41422-020-00442-0</ext-link></td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant <break/>DNA reagent</td><td valign="top">PMESy4-Nb35</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.molcel.2020.01.013">https://doi.org/10.1016/j.molcel.2020.01.013</ext-link></td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Recombinant <break/>DNA reagent</td><td valign="top">pcDNA3.1-GIPR (WT and mutants)−3Flag</td><td valign="top">This paper</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Peptide, recombinant protein</td><td valign="top">GIP<sub>1-42</sub></td><td valign="top">GenScript</td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Protease Inhibitor Cocktail, EDTA-Free</td><td valign="top">TragetMol</td><td valign="top">Cat # C0001</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Apyrase</td><td valign="top">Sigma-Aldrich (Merck)</td><td valign="top">Cat # A6132</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">TCEP</td><td valign="top">Sigma-Aldrich (Merck)</td><td valign="top">Cat # C4706</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Lauryl maltose neopentylglycol (LMNG)</td><td valign="top">Anatrace</td><td valign="top">Cat # NG310</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Cholesterol hemisuccinate (CHS)</td><td valign="top">Anatrace</td><td valign="top">Cat # CH210</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Glyco-diosgenin (GDN)</td><td valign="top">Anatrace</td><td valign="top">Cat # GDN101</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Amylose resin</td><td valign="top">NEB</td><td valign="top">Cat # E8021L</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">ESF 921 culture medium</td><td valign="top">Expression Systems</td><td valign="top">Cat # 96-00-01</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Fetal bovine serum (FBS)</td><td valign="top">Gibco</td><td valign="top">Cat # 10099–141</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">DMEM</td><td valign="top">Gibco</td><td valign="top">Cat # 12430–054</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">X-tremeGHNE HP DNA Transfection Reagent</td><td valign="top">Sigma-Aldrich (Roche)</td><td valign="top">Cat # 6366236001</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Digitonin</td><td valign="top">Biosynth</td><td valign="top">Cat # D-3203</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Salt active nuclease</td><td valign="top">Sigma-Aldrich</td><td valign="top">Cat # SRE0015-5KU</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Sodium pyruvate</td><td valign="top">Gibco</td><td valign="top">Cat # 11360–0’70</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Lipofectamine 2000 transfection reagent</td><td valign="top">Invitrogen</td><td valign="top">Cat # 11668–019</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top"><sup>125</sup>I-GIP</td><td valign="top">PerkinElmer</td><td valign="top">Cat # NEX402010UC</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">BSA</td><td valign="top">ABCONE</td><td valign="top">Cat # A23088-100G</td><td valign="top"/></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-Flag primary antibody</td><td valign="top">Sigma-Aldrich</td><td valign="top">Cat # F3165</td><td valign="top"/></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-mouse Alexa Fluor 488 conjugated secondary antibody</td><td valign="top">Invitrogen</td><td valign="top">Cat # A-21202</td><td valign="top"/></tr><tr><td valign="top">Commercial assay, kit</td><td valign="top">LANCE Ultra cAMP kit</td><td valign="top">PerkinElmer</td><td valign="top">Cat # 2675984</td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">MotionCor2.1</td><td valign="top">doi:<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1126/science.aav7942">10.1126/science.aav7942</ext-link></td><td valign="top">N/A</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://msg.ucsf.edu/em/software/motioncor2.html">https://msg.ucsf.edu/em/software/motioncor2.html</ext-link></td></tr><tr><td valign="top">Software, algorithm</td><td valign="top">Gctf v1.06</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jsb.2015.11.003">https://doi.org/10.1016/j.jsb.2015.11.003</ext-link></td><td valign="top">N/A</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://www2.mrc-lmb.cam.ac.uk/research/locally-developed-software/zhang-software/">https://www2.mrc-lmb.cam.ac.uk/research/locally-developed-software/zhang-software/</ext-link></td></tr><tr><td valign="top">Software, algorithm</td><td valign="top">RELION-3.0-beta2</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jsb.2012.09.006">https://doi.org/10.1016/j.jsb.2012.09.006</ext-link></td><td valign="top">N/A</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://www3.mrc-lmb.cam.ac.uk/relion/index.php/Download_%26_install">https://www3.mrc-lmb.cam.ac.uk/relion/index.php/Download_%26_install</ext-link></td></tr><tr><td valign="top">Software, algorithm</td><td valign="top">COOT</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1107/S0907444904019158">https://doi.org/10.1107/S0907444904019158</ext-link></td><td valign="top">N/A</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://www2.mrc-lmb.cam.ac.uk/personal/pemsley/coot/">https://www2.mrc-lmb.cam.ac.uk/personal/pemsley/coot/</ext-link></td></tr><tr><td valign="top">Software, algorithm</td><td valign="top">Phenix</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1107/S0907444909052925">https://doi.org/10.1107/S0907444909052925</ext-link></td><td valign="top">N/A</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="http://www.phenix-online.org/">http://www.phenix-online.org/</ext-link></td></tr><tr><td valign="top">Software, algorithm</td><td valign="top">Chimera</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/jcc.20084">https://doi.org/10.1002/jcc.20084</ext-link></td><td valign="top">N/A</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://www.cgl.ucsf.edu/chimera/">https://www.cgl.ucsf.edu/chimera/</ext-link></td></tr><tr><td valign="top">Software, algorithm</td><td valign="top">PyMOL</td><td valign="top">Schrödinger</td><td valign="top">N/A</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://pymol.org/2/">https://pymol.org/2/</ext-link></td></tr><tr><td valign="top">Software, algorithm</td><td valign="top">GraphPad Prism v7.0</td><td valign="top">GraphPad Software</td><td valign="top">N/A</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://www.graphpad.com/">https://www.graphpad.com/</ext-link></td></tr><tr><td valign="top">Software, algorithm</td><td valign="top">FreeSASA</td><td valign="top">doi:<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.12688/f1000research.7931.1">10.12688/f1000research.7931.1</ext-link></td><td valign="top">N/A</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="http://freesasa.github.io/">http://freesasa.github.io/</ext-link></td></tr><tr><td valign="top">Software, algorithm</td><td valign="top">Gromacs 2018.5</td><td valign="top">doi:<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.softx.2015.06.001">10.1016/j.softx.2015.06.001</ext-link></td><td valign="top">N/A</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://manual.gromacs.org/2018.5/download.html">https://manual.gromacs.org/2018.5/download.html</ext-link></td></tr><tr><td valign="top">Software, algorithm</td><td valign="top">Protein Preparation <break/>Wizard</td><td valign="top">Schrödinger</td><td valign="top">N/A</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://www.schrodinger.com/products/protein-preparation-wizard">https://www.schrodinger.com/products/protein-preparation-wizard</ext-link></td></tr><tr><td valign="top">Software, algorithm</td><td valign="top">CHARMM-GUI Membrane <break/>Builder</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/jcc.23702">https://doi.org/10.1002/jcc.23702</ext-link></td><td valign="top">N/A</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://charmm-gui.org/">https://charmm-gui.org/</ext-link></td></tr><tr><td valign="top">Software, algorithm</td><td valign="top">CHARMM36-CAMP</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1021/ct200328p">https://doi.org/10.1021/ct200328p</ext-link></td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">LINCS algorithm</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1021/ct700200b">https://doi.org/10.1021/ct700200b</ext-link></td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">Semi-isotropic Parrinello-Rahman barostat</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/0022-3093(93)90111-A">https://doi.org/10.1016/0022-3093(93)90111-A</ext-link></td><td valign="top">N/A</td><td valign="top"/></tr></tbody></table></table-wrap><sec id="s4-1"><title>Cell culture</title><p><italic>Spodoptera frugiperda</italic> (<italic>Sf</italic>9) (Invitrogen) and High-Five insect cells (ThermoFisher Scientific) were cultured in ESF 921 serum-free medium (Expression Systems) at 27°C and 120 rpm.</p></sec><sec id="s4-2"><title>Constructs</title><p>The human GIPR DNA (Genewiz) with one mutation (T345F) was cloned into a modified pFastBac vector (Invitrogen). The native signal peptide was replaced by the hemagglutinin signal peptide (HA) to enhance receptor expression. A BRIL fusion protein was added at the N-terminal of the ECD with a TEV protease site and 2GSA linker between them. Forty-five amino acids (Q422-C466) were truncated at the C terminus where LgBiT was added with a 15-amino acid (15AA) polypeptide linker in between, followed by a TEV protease cleavage site and an optimized maltose binding protein–maltose binding protein tag (OMBP-MBP). A dominant-negative bovine Gα<sub>s</sub> (DNGα<sub>s</sub>) (S54N, G226A, E268A, N271K, K274D, R280K, T284D, and I285T) construct was used to stabilize the complex (<xref ref-type="bibr" rid="bib51">Zhou et al., 2020</xref>; <xref ref-type="bibr" rid="bib26">Liang et al., 2018b</xref>). SmBiT34 (peptide 86, Promega) subunit was added to the C terminus of rat Gβ1 with a 15AA polypeptide linker between them. The modified rat Gβ1 and bovine Gγ2 were both cloned into a pFastBac vector.</p></sec><sec id="s4-3"><title>Protein expression</title><p>Baculoviruses containing the above complex construct were prepared by the Bac-to-Bac system (Invitrogen). GIPR and G<sub>s</sub> heterotrimer were co-expressed in High-Five cells. Briefly, insect cells were grown in ESF 921 culture medium (Expression Systems) to a density of 3.2 × 10<sup>6</sup> cells/mL, and then cells were infected with four kinds of viral preparations: BRIL-TEV-2GSA-GIPR(22-421)T345F-15AA-LgBiT-TEV-OMBP-MBP, Gα<sub>s</sub>, Gβ1-peptide 86, and Gγ2 at a ratio of 1:3:3:3. After 48 hr incubation at 27°C, the cells were collected by centrifugation and stored at −80°C until use.</p></sec><sec id="s4-4"><title>Nb35 expression and purification</title><p>Nanobody-35 (Nb35) with a 6× his tag at the C terminus was expressed in the periplasm of <italic>E. coli</italic> BL21 (DE3) cells. Briefly, Nb35 target gene was transformed in the bacterium and amplified in TB culture medium with 100 μg/mL ampicillin, 2 mM MgCl<sub>2</sub>, 0.1% (w/v) glucose at 37°C, 180 rpm. When OD600 reached 0.7–1.2, 1 mM IPTG was added to induce expression followed by overnight incubation at 28°C. The cell pellet was then collected at 3000 rpm under 4°C and stored at −80°C. Nb35 was purified as by size-exclusion chromatography using a HiLoad 16/600 Superdex 75 column (GE Healthcare) with running buffer containing 20 mM HEPES, 100 mM NaCl, pH 7.4. Fractions of Nb35 were concentrated to ~3 mg/mL and quickly frozen in the liquid nitrogen with 10% glycerol and stored in −80°C.</p></sec><sec id="s4-5"><title>Complex formation and purification</title><p>Cell pellets were lysed in a buffer consisting of 20 mM HEPES, 100 mM NaCl, pH 7.4, 10 mM MgCl<sub>2</sub>, 1 mM MnCl<sub>2</sub>, and 10% glycerol supplemented with protease inhibitor cocktail, EDTA-free (TragetMol). Subsequently, cell membranes were collected by ultracentrifugation at 4°C, 90,000 g for 35 min. The membranes were resuspended with a buffer containing 20 mM HEPES, 100 mM NaCl, pH 7.4, 10 mM MgCl<sub>2</sub>, 1 mM MnCl<sub>2</sub>, and 10% glycerol. The complex of GIPR-G<sub>s</sub> was assembled by adding 15 μM GIP<sub>1-42</sub> (GenScript), 100 μM TCEP, 25 mU/mL Apyrase (Sigma-Aldrich), 15 μg/mL Nb35, and 100 U salt active nuclease (Sigma-Aldrich) supplemented with protease inhibitor cocktail for 1.5 hr incubation at room temperature (RT). The preparation was then solubilized with 0.5% (w/v) lauryl maltose neopentylglycol (LMNG, Anatrace) and 0.1% (w/v) cholesterol hemisuccinate (CHS, Anatrace) with additional 1 μM GIP<sub>1-42</sub> for 3 hr at 4°C. The supernatant was isolated by centrifugation at 90,000 g for 35 min, and the solubilized complex was incubated with amylose resin (NEB) for 2.5 hr at 4°C. After batch binding, the resin was collected by centrifugation at 550 g and loaded onto a gravity flow column. The resin in column was firstly washed with five column volumes of buffer containing 20 mM HEPES, pH 7.4, 100 mM NaCl, 10% (v/v) glycerol, 5 mM MgCl<sub>2</sub>, 1 mM MnCl<sub>2</sub>, 25 μM TCEP, 3 μM GIP<sub>1-42</sub>, 0.1% (w/v) LMNG, and 0.02% (w/v) CHS. Subsequently, the resin was washed with 25 column volumes of buffer containing 20 mM HEPES, pH 7.4, 100 mM NaCl, 10% (v/v) glycerol, 5 mM MgCl<sub>2</sub>, 1 mM MnCl<sub>2</sub>, 25 μM TCEP, 3 μM GIP<sub>1-42</sub>, 0.03% (w/v) LMNG, 0.01% (w/v) glyco-diosgenin (GDN, Anatrace), and 0.008% (w/v) CHS. The protein was then incubated with a buffer containing 20 mM HEPES, pH 7.4, 100 mM NaCl, 10% (v/v) glycerol, 5 mM MgCl<sub>2</sub>, 1 mM MnCl<sub>2</sub>, 25 μM TCEP, 50 μM GIP<sub>1-42</sub>, 10 μg/mL Nb35, 0.03% (w/v) LMNG, 0.01% (w/v) glyco-diosgenin, 0.008% (w/v) CHS, and 30 μg/mL His-tagged TEV protease on the column overnight at 4°C. The flow through was collected and concentrated to 500 μL using a 100 kDa filter (Merck Millipore). Size-exclusion chromatography was performed by loading the protein onto Superose 6 Increase 10/300 GL (GE Healthcare) column with running buffer containing 20 mM HEPES, pH 7.4, 100 mM NaCl, 10 mM MgCl<sub>2</sub>, 100 μM TCEP, 5 μM GIP<sub>1-42</sub>, 0.00075% (w/v) LMNG, 0.00025% (w/v) glyco-diosgenin, 0.0002% (w/v) CHS, and 0.00025% digitonin (Anatrace). Monomeric GIPR-G<sub>s</sub> complexes were collected and concentrated for cryo-EM analysis.</p></sec><sec id="s4-6"><title>Data acquisition and image processing</title><p>The purified GIP<sub>1-42</sub>–GIPR–G<sub>s</sub>–Nb35 complex at a concentration of 6–7 mg/mL was mixed with 100 μM GIP<sub>1-42</sub> at 4°C and applied to glow-discharged holey carbon grids (Quantifoil R1.2/1.3, Au 300 mesh) that were subsequently vitrified by plunging into liquid ethane using a Vitrobot Mark IV (ThermoFisher Scientific). A Titan Krios equipped with a Gatan K3 Summit direct electron detector was used to acquire Cryo-EM images. The microscope was operated at 300 kV accelerating voltage, at a nominal magnification of 46,685× in counting mode, corresponding to a pixel size of 1.071 Å. Totally, 8023 movies were obtained with a defocus range of −1.2 to −2.2 μm. An accumulated dose of 80 electrons per Å<sup>2</sup> was fractionated into a movie stack of 36 frames.</p><p>Dose-fractionated image stacks were subjected to beam-induced motion correction using MotionCor2.1. A sum of all frames, filtered according to the exposure dose, in each image stack was used for further processing. Contrast transfer function parameters for each micrograph were determined by Gctf v1.06. Particle selection, 2D and 3D classifications were performed on a binned dataset with a pixel size of 2.142 Å using RELION-3.0-beta2. Auto-picking yielded 4,895,399 particle projections that were subjected to reference-free 2D classification to discard false-positive particles or particles categorized in poorly defined classes, producing 2,754,623 particle projections for further processing. This subset of particle projections was subjected to a round of maximum-likelihood-based three dimensional classifications with a pixel size of 2.142 Å, resulting in one well-defined subset with 1,395,031 projections. Further 3D classifications with mask on the receptor produced one good subset accounting for 565,239 particles, which were subjected to another round of 3D classifications with mask on the ECD. A selected subset containing 295,021 projections was then subjected to 3D refinement and Bayesian polishing with a pixel size of 1.071 Å. After the last round of refinement, the final map has an indicated global resolution of 2.94 Å at a Fourier shell correlation (FSC) of 0.143. Local resolution was determined using the Bsoft package with half maps as input maps.</p></sec><sec id="s4-7"><title>Model building and refinement</title><p>The cryo-EM structure of GCGR–G<sub>s</sub>–Nb35 complex (PDB code 6WPW) (<xref ref-type="bibr" rid="bib34">Qiao et al., 2020</xref>) and the crystal structure of GIPR ECD (PDB code 2QKH) (<xref ref-type="bibr" rid="bib31">Parthier et al., 2007</xref>) were used as the start for model building and refinement against the EM map. The model was docked into the EM density map using Chimera (<xref ref-type="bibr" rid="bib33">Pettersen et al., 2004</xref>), followed by iterative manual adjustment and rebuilding in COOT (<xref ref-type="bibr" rid="bib12">Emsley and Cowtan, 2004</xref>). Real space refinement was performed using Phenix (<xref ref-type="bibr" rid="bib1">Adams et al., 2010</xref>). The model statistics were validated using MolProbity (<xref ref-type="bibr" rid="bib7">Chen et al., 2010</xref>). Structural figures were prepared in Chimera and PyMOL (<ext-link ext-link-type="uri" xlink:href="https://pymol.org/2/">https://pymol.org/2/</ext-link>). The final refinement statistics are provided in <xref ref-type="table" rid="table1">Table 1</xref>.</p></sec><sec id="s4-8"><title>cAMP accumulation assay</title><p>GIP<sub>1-42</sub>-stimulated cAMP accumulation was measured by a LANCE Ultra cAMP kit (PerkinElmer). Briefly, HEK 293T cells were cultured in DMEM (Gibco) supplemented with 10% (v/v) fetal bovine serum (FBS, Gibco) and 1% (v/v) sodium pyruvate (Gibco) at 37°C, 5% CO<sub>2</sub>. Cells were seeded onto six-well cell culture plates and transiently transfected with different GIPR constructs using Lipofectamine 2000 transfection reagent (Invitrogen). All the mutant constructs were modified by single-point mutation in the setting of the WT construct (HA-Flag-3GSA-GIPR(22-466)). After 24 hr culture, the transfected cells were seeded onto 384-well microtiter plates at a density of 3000 cells per well in HBSS supplemented with 5 mM HEPES, 0.1% (w/v) bovine serum albumin (BSA), and 0.5 mM 3-isobutyl-1- methylxanthine. The cells were stimulated with different concentrations of GIP<sub>1-42</sub> for 40 min at RT. Eu and Ulight were then diluted by cAMP detection buffer and added to the plates separately to terminate the reaction. Plates were incubated at RT for 40 min and the fluorescence intensity measured at 620 nm and 650 nm by an EnVision multilabel plate reader (PerkinElmer).</p></sec><sec id="s4-9"><title>Whole-cell binding assay</title><p>CHO-K1 cells were cultured in F12 medium with 10% FBS and seeded at a density of 30,000 cells/well in Isoplate-96 plates (PerkinElmer). The WT (HA-Flag-3GSA-GIPR(22-466)) or mutant GIPR were transiently transfected using Lipofectamine 2000 transfection reagent. The mutant construct was modified by single-point mutation in the setting of the WT construct. Twenty-four hours after transfection, cells were washed twice, and incubated with blocking buffer (F12 supplemented with 33 mM HEPES and 0.1% BSA, pH 7.4) for 2 hr at 37°C. For homogeneous binding, cells were incubated in binding buffer with a constant concentration of <sup>125</sup>I-GIP (40 pM, PerkinElmer) and increasing concentrations of unlabeled GIP<sub>1-42</sub> (3.57 pM–1 μM) at RT for 3 hr. Following incubation, cells were washed three times with ice-cold PBS and lysed by addition of 50 μL lysis buffer (PBS supplemented with 20 mM Tris–HCl, 1% Triton X-100, pH 7.4). Fifty microliters of scintillation cocktail (OptiPhase SuperMix, PerkinElmer) was added, and the plates were subsequently counted for radioactivity (counts per minute, CPM) in a scintillation counter (MicroBeta2 Plate Counter, PerkinElmer).</p></sec><sec id="s4-10"><title>β-Arrestin2 recruitment</title><p>HEK 293T cells (3 × 10<sup>6</sup> cells/10 cm plate) were grown for 24 hr before transfection with 10.6 μg plasmid containing GIPR tagged with Rluc8 and β-arrestin with a Venus-tag in the N terminus at a ratio of 1:9. Transiently transfected cells were then seeded onto poly-<sc>d</sc>-lysine coated 96-well culture plates (50,000 cells/well) in DMEM with 10% FBS. Cells were grown overnight before incubation in assay buffer (HBSS supplemented with 10 mM HEPES and 0.1% BSA, pH 7.4) for 30 min at 37°C. Coelentrazine-h (Yeasen Biotech) was added to a final concentration of 5 μM for 5 min before bioluminescence resonance energy transfer (BRET) readings were made using an EnVision plate reader (PerkinElmer). BRET baseline measurements were collected for 10 cycles prior to ligand addition. Following peptide addition, BRET was measured for 50 cycles. The BRET signal (ratio of 535 nm over 470 nm emission) was corrected to the baseline and then vehicle-treated condition to determine ligand-induced changes in BRET response. Concentration–response values were obtained from the area-under-the-curve (AUC) of the responses elicited by GIP<sub>1-42</sub>.</p></sec><sec id="s4-11"><title>Receptor surface expression</title><p>Cell surface expression was determined by flow cytometry to the N-terminal Flag tag on the WT GIPR (HA-Flag-3GSA-GIPR(22-466)) and its mutants transiently expressed in HEK 293T cells. All the mutant constructs were modified by single-point mutation in the setting of the WT construct. Briefly, approximately 2 × 10<sup>5</sup> cells were blocked with PBS containing 5% BSA (w/v) at RT for 15 min and then incubated with 1:300 anti-Flag primary antibody (diluted with PBS containing 5% BSA, Sigma-Aldrich) at RT for 1 hr. The cells were then washed three times with PBS containing 1% BSA (w/v) followed by 1 hr incubation with 1:1000 anti-mouse Alexa Fluor 488 conjugated secondary antibody (diluted with PBS containing 5% BSA, Invitrogen) at RT in the dark. After washing three times, cells were re-suspended in 200 μL PBS containing 1% BSA for detection by NovoCyte (Agilent) utilizing laser excitation and emission wavelengths of 488 nm and 530 nm, respectively. For each sample, 20,000 cellular events were collected, and the total fluorescence intensity of positive expression cell population was calculated. Data were normalized to the WT receptor.</p></sec><sec id="s4-12"><title>Molecular dynamics simulations</title><p>Molecular dynamic simulations were performed by Gromacs 2018.5. The peptide–GIPR complexes were built based on the cryo-EM GIP–GIPR–G<sub>s</sub> complex and prepared by the Protein Preparation Wizard (Schrodinger 2017–4) with the G protein and Nb35 nanobody removed. The receptor chain termini were capped with acetyl and methylamide, and the titratable residues were left in their dominant state at pH 7.0. The complexes were embedded in a bilayer composed of 200 POPC lipids and solvated with 0.15 M NaCl in explicitly TIP3P waters using CHARMM-GUI Membrane Builder (<xref ref-type="bibr" rid="bib41">Wu et al., 2014</xref>). The CHARMM36-CAMP force filed (<xref ref-type="bibr" rid="bib16">Guvench et al., 2011</xref>) was adopted for protein, peptides, lipids, and salt ions. The Particle Mesh Ewald (PME) method was used to treat all electrostatic interactions beyond a cut-off of 10 Å, and the bonds involving hydrogen atoms were constrained using LINCS algorithm (<xref ref-type="bibr" rid="bib17">Hess, 2008</xref>). The complex system was firstly relaxed using the steepest descent energy minimization, followed by slow heating of the system to 310 K with restraints. The restraints were reduced gradually over 50 ns. Finally, restrain-free production run was carried out for each simulation, with a time step of 2 fs in the NPT ensemble at 310 K and 1 bar using the Nose–Hoover thermostat and the semi-isotropic Parrinello–Rahman barostat (<xref ref-type="bibr" rid="bib3">Aoki and Yonezawa, 1992</xref>), respectively. The buried interface areas were calculated with FreeSASA (<xref ref-type="bibr" rid="bib30">Mitternacht, 2016</xref>) using the Sharke–Rupley algorithm with a probe radius of 1.2 Å. The last 700 ns trajectory of each simulation was used to root mean square fluctuation (RMSF) calculation.</p></sec><sec id="s4-13"><title>Statistical analysis</title><p>All functional data were presented as means ± standard error of the mean (S.E.M.). Statistical analysis was performed using GraphPad Prism 7 (GraphPad Software). Concentration–response curves were evaluated with a three-parameter logistic equation. The significance was determined with either two-tailed Student’s <italic>t</italic>-test or one-way ANOVA. Significant difference is accepted at p&lt;0.001.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We thank Elita Yuliantie, Wen Sun, Zhaotong Cong, Fulai Zhou, Yuqi Ping, X Edward Zhou, Karsten Melcher, Jinhuan Chen, and Xijiang Pan for technical advice. The cryo-EM data were collected at Cryo-Electron Microscopy Research Center, Shanghai Institute of Materia Medica. This work was partially supported by National Natural Science Foundation of China 81872915 (M-WW), 32071203 (LHZ), 81773792 (DHY), 81973373 (DHY), and 21704064 (QTZ); National Science and Technology Major Project of China – Key New Drug Creation and Manufacturing Program 2018ZX09735–001 (M-WW) and 2018ZX09711002–002–005 (DHY); National Key Basic Research Program of China 2018YFA0507000 (M-WW); Ministry of Science and Technology of China 2018YFA0507002 (HEX); Shanghai Municipal Science and Technology Major Project 2019SHZDZX02 (HEX); Strategic Priority Research Program of Chinese Academy of Sciences XDB37030103 (HEX); Shanghai Municipality Science and Technology Development Fund 18430711500 (M-WW) and 18ZR1447800 (LHZ); Novo Nordisk-CAS Research Fund grant NNCAS-2017–1-CC (DHY); The Young Innovator Association of CAS 2018325 (LHZ); and SA-SIBS Scholarship Program (LHZ and DHY).</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Data curation, Software, Formal analysis, Validation, Visualization, Methodology, Writing - original draft</p></fn><fn fn-type="con" id="con2"><p>Data curation, Formal analysis, Validation, Methodology</p></fn><fn fn-type="con" id="con3"><p>Software, Formal analysis, Visualization, Methodology, Writing - original draft</p></fn><fn fn-type="con" id="con4"><p>Data curation, Formal analysis, Methodology</p></fn><fn fn-type="con" id="con5"><p>Software, Formal analysis, Visualization, Methodology, Writing - original draft</p></fn><fn fn-type="con" id="con6"><p>Data curation, Formal analysis, Validation, Methodology</p></fn><fn fn-type="con" id="con7"><p>Methodology</p></fn><fn fn-type="con" id="con8"><p>Data curation</p></fn><fn fn-type="con" id="con9"><p>Data curation, Validation, Methodology</p></fn><fn fn-type="con" id="con10"><p>Methodology</p></fn><fn fn-type="con" id="con11"><p>Methodology</p></fn><fn fn-type="con" id="con12"><p>Methodology</p></fn><fn fn-type="con" id="con13"><p>Software</p></fn><fn fn-type="con" id="con14"><p>Conceptualization</p></fn><fn fn-type="con" id="con15"><p>Conceptualization, Resources, Supervision, Funding acquisition, Investigation, Project administration, Writing - review and editing</p></fn><fn fn-type="con" id="con16"><p>Resources, Data curation, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Methodology, Writing - original draft, Project administration, Writing - review and editing</p></fn><fn fn-type="con" id="con17"><p>Resources, Data curation, Formal analysis, Supervision, Funding acquisition, Investigation, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con18"><p>Conceptualization, Resources, Formal analysis, Supervision, Funding acquisition, Investigation, Methodology, Writing - original draft, Project administration, Writing - review and editing</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="sdata1"><label>Source data 1.</label><caption><title>All the source data files.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-68719-data1-v2.zip"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-68719-transrepform-v2.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>Atomic coordinates of the GIP-GIPR-G<sub>s</sub> complex have been deposited in the Protein Data Bank under accession code 7DTY and Electron Microscopy Data Bank (EMDB) accession code EMD-30860. All data generated or analysed during this study are included in the manuscript and supporting files. Source data files have been provided for Figure 2, Figure 1—figure supplement 1 and Figure 4—figure supplement 4.</p><p>The following dataset was generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name><name><surname>Hang</surname><given-names>K</given-names></name><name><surname>Zou</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>F</given-names></name><name><surname>Rao</surname><given-names>Q</given-names></name><name><surname>Dai</surname><given-names>A</given-names></name><name><surname>Yin</surname><given-names>W</given-names></name><name><surname>Shen</surname><given-names>DD</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Xia</surname><given-names>T</given-names></name><name><surname>Stevens</surname><given-names>RC</given-names></name><name><surname>Xu</surname><given-names>HE</given-names></name><name><surname>Yang</surname><given-names>D</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>MW</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>Structural basis of ligand selectivity conferred by the human glucose-dependent insulinotropic polypeptide receptor</data-title><source>Electron Microscopy Data Bank</source><pub-id assigning-authority="EBI" pub-id-type="accession" xlink:href="https://www.ebi.ac.uk/pdbe/entry/emdb/EMD-30860">EMD-30860</pub-id></element-citation></p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname> <given-names>PD</given-names></name><name><surname>Afonine</surname> <given-names>PV</given-names></name><name><surname>Bunkóczi</surname> <given-names>G</given-names></name><name><surname>Chen</surname> <given-names>VB</given-names></name><name><surname>Davis</surname> <given-names>IW</given-names></name><name><surname>Echols</surname> <given-names>N</given-names></name><name><surname>Headd</surname> <given-names>JJ</given-names></name><name><surname>Hung</surname> <given-names>LW</given-names></name><name><surname>Kapral</surname> <given-names>GJ</given-names></name><name><surname>Grosse-Kunstleve</surname> <given-names>RW</given-names></name><name><surname>McCoy</surname> <given-names>AJ</given-names></name><name><surname>Moriarty</surname> <given-names>NW</given-names></name><name><surname>Oeffner</surname> <given-names>R</given-names></name><name><surname>Read</surname> <given-names>RJ</given-names></name><name><surname>Richardson</surname> <given-names>DC</given-names></name><name><surname>Richardson</surname> <given-names>JS</given-names></name><name><surname>Terwilliger</surname> <given-names>TC</given-names></name><name><surname>Zwart</surname> <given-names>PH</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>PHENIX: a comprehensive Python-based system for macromolecular structure solution</article-title><source>Acta Crystallographica Section D Biological Crystallography</source><volume>66</volume><fpage>213</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1107/S0907444909052925</pub-id><pub-id pub-id-type="pmid">20124702</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alexiadou</surname> <given-names>K</given-names></name><name><surname>Anyiam</surname> <given-names>O</given-names></name><name><surname>Tan</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Cracking the combination: Gut hormones for the treatment of obesity and diabetes</article-title><source>Journal of Neuroendocrinology</source><volume>31</volume><elocation-id>e12664</elocation-id><pub-id pub-id-type="doi">10.1111/jne.12664</pub-id><pub-id pub-id-type="pmid">30466162</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aoki</surname> <given-names>KM</given-names></name><name><surname>Yonezawa</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>Constant-pressure molecular-dynamics simulations of the crystal-smectic transition in systems of soft parallel spherocylinders</article-title><source>Physical Review A</source><volume>46</volume><fpage>6541</fpage><lpage>6549</lpage><pub-id pub-id-type="doi">10.1103/PhysRevA.46.6541</pub-id><pub-id pub-id-type="pmid">9907963</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bailey</surname> <given-names>CJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>GIP analogues and the treatment of obesity-diabetes</article-title><source>Peptides</source><volume>125</volume><elocation-id>170202</elocation-id><pub-id pub-id-type="doi">10.1016/j.peptides.2019.170202</pub-id><pub-id pub-id-type="pmid">31756366</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bastin</surname> <given-names>M</given-names></name><name><surname>Andreelli</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Dual GIP-GLP1-Receptor agonists in the treatment of type 2 diabetes: a short review on emerging data and therapeutic potential</article-title><source>Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy</source><volume>12</volume><fpage>1973</fpage><lpage>1985</lpage><pub-id pub-id-type="doi">10.2147/DMSO.S191438</pub-id><pub-id pub-id-type="pmid">31686879</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname> <given-names>R</given-names></name><name><surname>Zhang</surname> <given-names>X</given-names></name><name><surname>Qiao</surname> <given-names>A</given-names></name><name><surname>Dai</surname> <given-names>A</given-names></name><name><surname>Belousoff</surname> <given-names>MJ</given-names></name><name><surname>Tan</surname> <given-names>Q</given-names></name><name><surname>Shao</surname> <given-names>L</given-names></name><name><surname>Zhong</surname> <given-names>L</given-names></name><name><surname>Lin</surname> <given-names>G</given-names></name><name><surname>Liang</surname> <given-names>YL</given-names></name><name><surname>Ma</surname> <given-names>L</given-names></name><name><surname>Han</surname> <given-names>S</given-names></name><name><surname>Yang</surname> <given-names>D</given-names></name><name><surname>Danev</surname> <given-names>R</given-names></name><name><surname>Wang</surname> <given-names>MW</given-names></name><name><surname>Wootten</surname> <given-names>D</given-names></name><name><surname>Wu</surname> <given-names>B</given-names></name><name><surname>Sexton</surname> <given-names>PM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Cryo-electron microscopy structure of the glucagon receptor with a dual-agonist peptide</article-title><source>Journal of Biological Chemistry</source><volume>295</volume><fpage>9313</fpage><lpage>9325</lpage><pub-id pub-id-type="doi">10.1074/jbc.RA120.013793</pub-id><pub-id pub-id-type="pmid">32371397</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>VB</given-names></name><name><surname>Arendall</surname> <given-names>WB</given-names></name><name><surname>Headd</surname> <given-names>JJ</given-names></name><name><surname>Keedy</surname> <given-names>DA</given-names></name><name><surname>Immormino</surname> <given-names>RM</given-names></name><name><surname>Kapral</surname> <given-names>GJ</given-names></name><name><surname>Murray</surname> <given-names>LW</given-names></name><name><surname>Richardson</surname> <given-names>JS</given-names></name><name><surname>Richardson</surname> <given-names>DC</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>MolProbity: all-atom structure validation for macromolecular crystallography</article-title><source>Acta Crystallographica Section D Biological Crystallography</source><volume>66</volume><fpage>12</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1107/S0907444909042073</pub-id><pub-id pub-id-type="pmid">20057044</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coskun</surname> <given-names>T</given-names></name><name><surname>Sloop</surname> <given-names>KW</given-names></name><name><surname>Loghin</surname> <given-names>C</given-names></name><name><surname>Alsina-Fernandez</surname> <given-names>J</given-names></name><name><surname>Urva</surname> <given-names>S</given-names></name><name><surname>Bokvist</surname> <given-names>KB</given-names></name><name><surname>Cui</surname> <given-names>X</given-names></name><name><surname>Briere</surname> <given-names>DA</given-names></name><name><surname>Cabrera</surname> <given-names>O</given-names></name><name><surname>Roell</surname> <given-names>WC</given-names></name><name><surname>Kuchibhotla</surname> <given-names>U</given-names></name><name><surname>Moyers</surname> <given-names>JS</given-names></name><name><surname>Benson</surname> <given-names>CT</given-names></name><name><surname>Gimeno</surname> <given-names>RE</given-names></name><name><surname>D'Alessio</surname> <given-names>DA</given-names></name><name><surname>Haupt</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept</article-title><source>Molecular Metabolism</source><volume>18</volume><fpage>3</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/j.molmet.2018.09.009</pub-id><pub-id pub-id-type="pmid">30473097</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Darbalaei</surname> <given-names>S</given-names></name><name><surname>Yuliantie</surname> <given-names>E</given-names></name><name><surname>Dai</surname> <given-names>A</given-names></name><name><surname>Chang</surname> <given-names>R</given-names></name><name><surname>Zhao</surname> <given-names>P</given-names></name><name><surname>Yang</surname> <given-names>D</given-names></name><name><surname>Wang</surname> <given-names>MW</given-names></name><name><surname>Sexton</surname> <given-names>PM</given-names></name><name><surname>Wootten</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Evaluation of biased agonism mediated by dual agonists of the GLP-1 and glucagon receptors</article-title><source>Biochemical Pharmacology</source><volume>180</volume><elocation-id>114150</elocation-id><pub-id pub-id-type="doi">10.1016/j.bcp.2020.114150</pub-id><pub-id pub-id-type="pmid">32682761</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname> <given-names>M</given-names></name><name><surname>Deganutti</surname> <given-names>G</given-names></name><name><surname>Piper</surname> <given-names>SJ</given-names></name><name><surname>Liang</surname> <given-names>YL</given-names></name><name><surname>Khoshouei</surname> <given-names>M</given-names></name><name><surname>Belousoff</surname> <given-names>MJ</given-names></name><name><surname>Harikumar</surname> <given-names>KG</given-names></name><name><surname>Reynolds</surname> <given-names>CA</given-names></name><name><surname>Glukhova</surname> <given-names>A</given-names></name><name><surname>Furness</surname> <given-names>SGB</given-names></name><name><surname>Christopoulos</surname> <given-names>A</given-names></name><name><surname>Danev</surname> <given-names>R</given-names></name><name><surname>Wootten</surname> <given-names>D</given-names></name><name><surname>Sexton</surname> <given-names>PM</given-names></name><name><surname>Miller</surname> <given-names>LJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Structure and dynamics of the active Gs-coupled human secretin receptor</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>4137</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-17791-4</pub-id><pub-id pub-id-type="pmid">32811827</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duan</surname> <given-names>J</given-names></name><name><surname>Shen</surname> <given-names>DD</given-names></name><name><surname>Zhou</surname> <given-names>XE</given-names></name><name><surname>Bi</surname> <given-names>P</given-names></name><name><surname>Liu</surname> <given-names>QF</given-names></name><name><surname>Tan</surname> <given-names>YX</given-names></name><name><surname>Zhuang</surname> <given-names>YW</given-names></name><name><surname>Zhang</surname> <given-names>HB</given-names></name><name><surname>Xu</surname> <given-names>PY</given-names></name><name><surname>Huang</surname> <given-names>SJ</given-names></name><name><surname>Ma</surname> <given-names>SS</given-names></name><name><surname>He</surname> <given-names>XH</given-names></name><name><surname>Melcher</surname> <given-names>K</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Xu</surname> <given-names>HE</given-names></name><name><surname>Jiang</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Cryo-EM structure of an activated VIP1 receptor-G protein complex revealed by a NanoBiT tethering strategy</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>4121</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-17933-8</pub-id><pub-id pub-id-type="pmid">32807782</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emsley</surname> <given-names>P</given-names></name><name><surname>Cowtan</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Coot: model-building tools for molecular graphics</article-title><source>Acta Crystallographica Section D Biological Crystallography</source><volume>60</volume><fpage>2126</fpage><lpage>2132</lpage><pub-id pub-id-type="doi">10.1107/S0907444904019158</pub-id><pub-id pub-id-type="pmid">15572765</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faivre</surname> <given-names>E</given-names></name><name><surname>Hölscher</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Neuroprotective effects of D-Ala(2)GIP on Alzheimer's disease biomarkers in an APP/PS1 mouse model</article-title><source>Alzheimer's Research &amp; Therapy</source><volume>5</volume><elocation-id>20</elocation-id><pub-id pub-id-type="doi">10.1186/alzrt174</pub-id><pub-id pub-id-type="pmid">23601582</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finan</surname> <given-names>B</given-names></name><name><surname>Clemmensen</surname> <given-names>C</given-names></name><name><surname>Zhu</surname> <given-names>Z</given-names></name><name><surname>Stemmer</surname> <given-names>K</given-names></name><name><surname>Gauthier</surname> <given-names>K</given-names></name><name><surname>Müller</surname> <given-names>L</given-names></name><name><surname>De Angelis</surname> <given-names>M</given-names></name><name><surname>Moreth</surname> <given-names>K</given-names></name><name><surname>Neff</surname> <given-names>F</given-names></name><name><surname>Perez-Tilve</surname> <given-names>D</given-names></name><name><surname>Fischer</surname> <given-names>K</given-names></name><name><surname>Lutter</surname> <given-names>D</given-names></name><name><surname>Sánchez-Garrido</surname> <given-names>MA</given-names></name><name><surname>Liu</surname> <given-names>P</given-names></name><name><surname>Tuckermann</surname> <given-names>J</given-names></name><name><surname>Malehmir</surname> <given-names>M</given-names></name><name><surname>Healy</surname> <given-names>ME</given-names></name><name><surname>Weber</surname> <given-names>A</given-names></name><name><surname>Heikenwalder</surname> <given-names>M</given-names></name><name><surname>Jastroch</surname> <given-names>M</given-names></name><name><surname>Kleinert</surname> <given-names>M</given-names></name><name><surname>Jall</surname> <given-names>S</given-names></name><name><surname>Brandt</surname> <given-names>S</given-names></name><name><surname>Flamant</surname> <given-names>F</given-names></name><name><surname>Schramm</surname> <given-names>KW</given-names></name><name><surname>Biebermann</surname> <given-names>H</given-names></name><name><surname>Döring</surname> <given-names>Y</given-names></name><name><surname>Weber</surname> <given-names>C</given-names></name><name><surname>Habegger</surname> <given-names>KM</given-names></name><name><surname>Keuper</surname> <given-names>M</given-names></name><name><surname>Gelfanov</surname> <given-names>V</given-names></name><name><surname>Liu</surname> <given-names>F</given-names></name><name><surname>Köhrle</surname> <given-names>J</given-names></name><name><surname>Rozman</surname> <given-names>J</given-names></name><name><surname>Fuchs</surname> <given-names>H</given-names></name><name><surname>Gailus-Durner</surname> <given-names>V</given-names></name><name><surname>Hrabě de Angelis</surname> <given-names>M</given-names></name><name><surname>Hofmann</surname> <given-names>SM</given-names></name><name><surname>Yang</surname> <given-names>B</given-names></name><name><surname>Tschöp</surname> <given-names>MH</given-names></name><name><surname>DiMarchi</surname> <given-names>R</given-names></name><name><surname>Müller</surname> <given-names>TD</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Chemical Hybridization of Glucagon and Thyroid Hormone Optimizes Therapeutic Impact for Metabolic Disease</article-title><source>Cell</source><volume>167</volume><fpage>e814</fpage><lpage>e857</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.09.014</pub-id><pub-id pub-id-type="pmid">27720451</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gabe</surname> <given-names>MBN</given-names></name><name><surname>van der Velden</surname> <given-names>WJC</given-names></name><name><surname>Smit</surname> <given-names>FX</given-names></name><name><surname>Gasbjerg</surname> <given-names>LS</given-names></name><name><surname>Rosenkilde</surname> <given-names>MM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Molecular interactions of full-length and truncated GIP peptides with the GIP receptor - A comprehensive review</article-title><source>Peptides</source><volume>125</volume><elocation-id>170224</elocation-id><pub-id pub-id-type="doi">10.1016/j.peptides.2019.170224</pub-id><pub-id pub-id-type="pmid">31809770</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guvench</surname> <given-names>O</given-names></name><name><surname>Mallajosyula</surname> <given-names>SS</given-names></name><name><surname>Raman</surname> <given-names>EP</given-names></name><name><surname>Hatcher</surname> <given-names>E</given-names></name><name><surname>Vanommeslaeghe</surname> <given-names>K</given-names></name><name><surname>Foster</surname> <given-names>TJ</given-names></name><name><surname>Jamison</surname> <given-names>FW</given-names></name><name><surname>Mackerell</surname> <given-names>AD</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>CHARMM additive all-atom force field for carbohydrate derivatives and its utility in polysaccharide and carbohydrate-protein modeling</article-title><source>Journal of Chemical Theory and Computation</source><volume>7</volume><fpage>3162</fpage><lpage>3180</lpage><pub-id pub-id-type="doi">10.1021/ct200328p</pub-id><pub-id pub-id-type="pmid">22125473</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hess</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>P-LINCS: A Parallel Linear Constraint Solver for Molecular Simulation</article-title><source>Journal of Chemical Theory and Computation</source><volume>4</volume><fpage>116</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1021/ct700200b</pub-id><pub-id pub-id-type="pmid">26619985</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hilger</surname> <given-names>D</given-names></name><name><surname>Kumar</surname> <given-names>KK</given-names></name><name><surname>Hu</surname> <given-names>H</given-names></name><name><surname>Pedersen</surname> <given-names>MF</given-names></name><name><surname>O'Brien</surname> <given-names>ES</given-names></name><name><surname>Giehm</surname> <given-names>L</given-names></name><name><surname>Jennings</surname> <given-names>C</given-names></name><name><surname>Eskici</surname> <given-names>G</given-names></name><name><surname>Inoue</surname> <given-names>A</given-names></name><name><surname>Lerch</surname> <given-names>M</given-names></name><name><surname>Mathiesen</surname> <given-names>JM</given-names></name><name><surname>Skiniotis</surname> <given-names>G</given-names></name><name><surname>Kobilka</surname> <given-names>BK</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Structural insights into differences in G protein activation by family A and family B GPCRs</article-title><source>Science</source><volume>369</volume><elocation-id>eaba3373</elocation-id><pub-id pub-id-type="doi">10.1126/science.aba3373</pub-id><pub-id pub-id-type="pmid">32732395</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoare</surname> <given-names>SR</given-names></name><name><surname>Bonner</surname> <given-names>TI</given-names></name><name><surname>Usdin</surname> <given-names>TB</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Comparison of rat and human parathyroid hormone 2 (PTH2) receptor activation: PTH is a low potency partial agonist at the rat PTH2 receptor</article-title><source>Endocrinology</source><volume>140</volume><fpage>4419</fpage><lpage>4425</lpage><pub-id pub-id-type="doi">10.1210/endo.140.10.7040</pub-id><pub-id pub-id-type="pmid">10499494</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jazayeri</surname> <given-names>A</given-names></name><name><surname>Doré</surname> <given-names>AS</given-names></name><name><surname>Lamb</surname> <given-names>D</given-names></name><name><surname>Krishnamurthy</surname> <given-names>H</given-names></name><name><surname>Southall</surname> <given-names>SM</given-names></name><name><surname>Baig</surname> <given-names>AH</given-names></name><name><surname>Bortolato</surname> <given-names>A</given-names></name><name><surname>Koglin</surname> <given-names>M</given-names></name><name><surname>Robertson</surname> <given-names>NJ</given-names></name><name><surname>Errey</surname> <given-names>JC</given-names></name><name><surname>Andrews</surname> <given-names>SP</given-names></name><name><surname>Teobald</surname> <given-names>I</given-names></name><name><surname>Brown</surname> <given-names>AJ</given-names></name><name><surname>Cooke</surname> <given-names>RM</given-names></name><name><surname>Weir</surname> <given-names>M</given-names></name><name><surname>Marshall</surname> <given-names>FH</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Extra-helical binding site of a glucagon receptor antagonist</article-title><source>Nature</source><volume>533</volume><fpage>274</fpage><lpage>277</lpage><pub-id pub-id-type="doi">10.1038/nature17414</pub-id><pub-id pub-id-type="pmid">27111510</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kerr</surname> <given-names>BD</given-names></name><name><surname>Flatt</surname> <given-names>AJ</given-names></name><name><surname>Flatt</surname> <given-names>PR</given-names></name><name><surname>Gault</surname> <given-names>VA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Characterization and biological actions of N-terminal truncated forms of glucose-dependent insulinotropic polypeptide</article-title><source>Biochemical and Biophysical Research Communications</source><volume>404</volume><fpage>870</fpage><lpage>876</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2010.12.077</pub-id><pub-id pub-id-type="pmid">21184739</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname> <given-names>SJ</given-names></name><name><surname>Nian</surname> <given-names>C</given-names></name><name><surname>McIntosh</surname> <given-names>CH</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Activation of lipoprotein lipase by glucose-dependent insulinotropic polypeptide in adipocytes. A role for a protein kinase B, LKB1, and AMP-activated protein kinase cascade</article-title><source>The Journal of biological chemistry</source><volume>282</volume><fpage>8557</fpage><lpage>8567</lpage><pub-id pub-id-type="doi">10.1074/jbc.M609088200</pub-id><pub-id pub-id-type="pmid">17244606</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koth</surname> <given-names>CM</given-names></name><name><surname>Murray</surname> <given-names>JM</given-names></name><name><surname>Mukund</surname> <given-names>S</given-names></name><name><surname>Madjidi</surname> <given-names>A</given-names></name><name><surname>Minn</surname> <given-names>A</given-names></name><name><surname>Clarke</surname> <given-names>HJ</given-names></name><name><surname>Wong</surname> <given-names>T</given-names></name><name><surname>Chiang</surname> <given-names>V</given-names></name><name><surname>Luis</surname> <given-names>E</given-names></name><name><surname>Estevez</surname> <given-names>A</given-names></name><name><surname>Rondon</surname> <given-names>J</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Hötzel</surname> <given-names>I</given-names></name><name><surname>Allan</surname> <given-names>BB</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Molecular basis for negative regulation of the glucagon receptor</article-title><source>PNAS</source><volume>109</volume><fpage>14393</fpage><lpage>14398</lpage><pub-id pub-id-type="doi">10.1073/pnas.1206734109</pub-id><pub-id pub-id-type="pmid">22908259</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lagerström</surname> <given-names>MC</given-names></name><name><surname>Schiöth</surname> <given-names>HB</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Structural diversity of G protein-coupled receptors and significance for drug discovery</article-title><source>Nature Reviews Drug Discovery</source><volume>7</volume><fpage>339</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1038/nrd2518</pub-id><pub-id pub-id-type="pmid">18382464</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname> <given-names>YL</given-names></name><name><surname>Khoshouei</surname> <given-names>M</given-names></name><name><surname>Deganutti</surname> <given-names>G</given-names></name><name><surname>Glukhova</surname> <given-names>A</given-names></name><name><surname>Koole</surname> <given-names>C</given-names></name><name><surname>Peat</surname> <given-names>TS</given-names></name><name><surname>Radjainia</surname> <given-names>M</given-names></name><name><surname>Plitzko</surname> <given-names>JM</given-names></name><name><surname>Baumeister</surname> <given-names>W</given-names></name><name><surname>Miller</surname> <given-names>LJ</given-names></name><name><surname>Hay</surname> <given-names>DL</given-names></name><name><surname>Christopoulos</surname> <given-names>A</given-names></name><name><surname>Reynolds</surname> <given-names>CA</given-names></name><name><surname>Wootten</surname> <given-names>D</given-names></name><name><surname>Sexton</surname> <given-names>PM</given-names></name></person-group><year iso-8601-date="2018">2018a</year><article-title>Cryo-EM structure of the active, G<sub>s</sub>-protein complexed, human CGRP receptor</article-title><source>Nature</source><volume>561</volume><fpage>492</fpage><lpage>497</lpage><pub-id pub-id-type="doi">10.1038/s41586-018-0535-y</pub-id><pub-id pub-id-type="pmid">30209400</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname> <given-names>YL</given-names></name><name><surname>Zhao</surname> <given-names>P</given-names></name><name><surname>Draper-Joyce</surname> <given-names>C</given-names></name><name><surname>Baltos</surname> <given-names>JA</given-names></name><name><surname>Glukhova</surname> <given-names>A</given-names></name><name><surname>Truong</surname> <given-names>TT</given-names></name><name><surname>May</surname> <given-names>LT</given-names></name><name><surname>Christopoulos</surname> <given-names>A</given-names></name><name><surname>Wootten</surname> <given-names>D</given-names></name><name><surname>Sexton</surname> <given-names>PM</given-names></name><name><surname>Furness</surname> <given-names>SGB</given-names></name></person-group><year iso-8601-date="2018">2018b</year><article-title>Dominant Negative G Proteins Enhance Formation and Purification of Agonist-GPCR-G Protein Complexes for Structure Determination</article-title><source>ACS Pharmacology &amp; Translational Science</source><volume>1</volume><fpage>12</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1021/acsptsci.8b00017</pub-id><pub-id pub-id-type="pmid">32219201</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname> <given-names>Y-L</given-names></name><name><surname>Belousoff</surname> <given-names>MJ</given-names></name><name><surname>Zhao</surname> <given-names>P</given-names></name><name><surname>Koole</surname> <given-names>C</given-names></name><name><surname>Fletcher</surname> <given-names>MM</given-names></name><name><surname>Truong</surname> <given-names>TT</given-names></name><name><surname>Julita</surname> <given-names>V</given-names></name><name><surname>Christopoulos</surname> <given-names>G</given-names></name><name><surname>Xu</surname> <given-names>HE</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Khoshouei</surname> <given-names>M</given-names></name><name><surname>Christopoulos</surname> <given-names>A</given-names></name><name><surname>Danev</surname> <given-names>R</given-names></name><name><surname>Sexton</surname> <given-names>PM</given-names></name><name><surname>Wootten</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Toward a Structural Understanding of Class B GPCR Peptide Binding and Activation</article-title><source>Molecular Cell</source><volume>77</volume><fpage>e655</fpage><lpage>e668</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2020.01.012</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Longuet</surname> <given-names>C</given-names></name><name><surname>Sinclair</surname> <given-names>EM</given-names></name><name><surname>Maida</surname> <given-names>A</given-names></name><name><surname>Baggio</surname> <given-names>LL</given-names></name><name><surname>Maziarz</surname> <given-names>M</given-names></name><name><surname>Charron</surname> <given-names>MJ</given-names></name><name><surname>Drucker</surname> <given-names>DJ</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>The glucagon receptor is required for the adaptive metabolic response to fasting</article-title><source>Cell Metabolism</source><volume>8</volume><fpage>359</fpage><lpage>371</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2008.09.008</pub-id><pub-id pub-id-type="pmid">19046568</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname> <given-names>S</given-names></name><name><surname>Shen</surname> <given-names>Q</given-names></name><name><surname>Zhao</surname> <given-names>LH</given-names></name><name><surname>Mao</surname> <given-names>C</given-names></name><name><surname>Zhou</surname> <given-names>XE</given-names></name><name><surname>Shen</surname> <given-names>DD</given-names></name><name><surname>de Waal</surname> <given-names>PW</given-names></name><name><surname>Bi</surname> <given-names>P</given-names></name><name><surname>Li</surname> <given-names>C</given-names></name><name><surname>Jiang</surname> <given-names>Y</given-names></name><name><surname>Wang</surname> <given-names>MW</given-names></name><name><surname>Sexton</surname> <given-names>PM</given-names></name><name><surname>Wootten</surname> <given-names>D</given-names></name><name><surname>Melcher</surname> <given-names>K</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Xu</surname> <given-names>HE</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Molecular Basis for Hormone Recognition and Activation of Corticotropin-Releasing Factor Receptors</article-title><source>Molecular Cell</source><volume>77</volume><fpage>e664</fpage><lpage>e680</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2020.01.013</pub-id><pub-id pub-id-type="pmid">32004470</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitternacht</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>FreeSASA: An open source C library for solvent accessible surface area calculations</article-title><source>F1000Research</source><volume>5</volume><elocation-id>189</elocation-id><pub-id pub-id-type="doi">10.12688/f1000research.7931.1</pub-id><pub-id pub-id-type="pmid">26973785</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parthier</surname> <given-names>C</given-names></name><name><surname>Kleinschmidt</surname> <given-names>M</given-names></name><name><surname>Neumann</surname> <given-names>P</given-names></name><name><surname>Rudolph</surname> <given-names>R</given-names></name><name><surname>Manhart</surname> <given-names>S</given-names></name><name><surname>Schlenzig</surname> <given-names>D</given-names></name><name><surname>Fanghänel</surname> <given-names>J</given-names></name><name><surname>Rahfeld</surname> <given-names>JU</given-names></name><name><surname>Demuth</surname> <given-names>HU</given-names></name><name><surname>Stubbs</surname> <given-names>MT</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Crystal structure of the incretin-bound extracellular domain of a G protein-coupled receptor</article-title><source>PNAS</source><volume>104</volume><fpage>13942</fpage><lpage>13947</lpage><pub-id pub-id-type="doi">10.1073/pnas.0706404104</pub-id><pub-id pub-id-type="pmid">17715056</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parthier</surname> <given-names>C</given-names></name><name><surname>Reedtz-Runge</surname> <given-names>S</given-names></name><name><surname>Rudolph</surname> <given-names>R</given-names></name><name><surname>Stubbs</surname> <given-names>MT</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Passing the baton in class B GPCRs: peptide hormone activation via helix induction?</article-title><source>Trends in Biochemical Sciences</source><volume>34</volume><fpage>303</fpage><lpage>310</lpage><pub-id pub-id-type="doi">10.1016/j.tibs.2009.02.004</pub-id><pub-id pub-id-type="pmid">19446460</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pettersen</surname> <given-names>EF</given-names></name><name><surname>Goddard</surname> <given-names>TD</given-names></name><name><surname>Huang</surname> <given-names>CC</given-names></name><name><surname>Couch</surname> <given-names>GS</given-names></name><name><surname>Greenblatt</surname> <given-names>DM</given-names></name><name><surname>Meng</surname> <given-names>EC</given-names></name><name><surname>Ferrin</surname> <given-names>TE</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>UCSF Chimera--a visualization system for exploratory research and analysis</article-title><source>Journal of Computational Chemistry</source><volume>25</volume><fpage>1605</fpage><lpage>1612</lpage><pub-id pub-id-type="doi">10.1002/jcc.20084</pub-id><pub-id pub-id-type="pmid">15264254</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiao</surname> <given-names>A</given-names></name><name><surname>Han</surname> <given-names>S</given-names></name><name><surname>Li</surname> <given-names>X</given-names></name><name><surname>Li</surname> <given-names>Z</given-names></name><name><surname>Zhao</surname> <given-names>P</given-names></name><name><surname>Dai</surname> <given-names>A</given-names></name><name><surname>Chang</surname> <given-names>R</given-names></name><name><surname>Tai</surname> <given-names>L</given-names></name><name><surname>Tan</surname> <given-names>Q</given-names></name><name><surname>Chu</surname> <given-names>X</given-names></name><name><surname>Ma</surname> <given-names>L</given-names></name><name><surname>Thorsen</surname> <given-names>TS</given-names></name><name><surname>Reedtz-Runge</surname> <given-names>S</given-names></name><name><surname>Yang</surname> <given-names>D</given-names></name><name><surname>Wang</surname> <given-names>MW</given-names></name><name><surname>Sexton</surname> <given-names>PM</given-names></name><name><surname>Wootten</surname> <given-names>D</given-names></name><name><surname>Sun</surname> <given-names>F</given-names></name><name><surname>Zhao</surname> <given-names>Q</given-names></name><name><surname>Wu</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Structural basis of G<sub>s</sub> and G<sub>1</sub> recognition by the human glucagon receptor</article-title><source>Science</source><volume>367</volume><fpage>1346</fpage><lpage>1352</lpage><pub-id pub-id-type="doi">10.1126/science.aaz5346</pub-id><pub-id pub-id-type="pmid">32193322</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seino</surname> <given-names>Y</given-names></name><name><surname>Fukushima</surname> <given-names>M</given-names></name><name><surname>Yabe</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>GIP and GLP-1, the two incretin hormones: Similarities and differences</article-title><source>Journal of Diabetes Investigation</source><volume>1</volume><fpage>8</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1111/j.2040-1124.2010.00022.x</pub-id><pub-id pub-id-type="pmid">24843404</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skow</surname> <given-names>MA</given-names></name><name><surname>Bergmann</surname> <given-names>NC</given-names></name><name><surname>Knop</surname> <given-names>FK</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'</article-title><source>Diabetes, Obesity and Metabolism</source><volume>18</volume><fpage>847</fpage><lpage>854</lpage><pub-id pub-id-type="doi">10.1111/dom.12685</pub-id><pub-id pub-id-type="pmid">27160961</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sparre-Ulrich</surname> <given-names>AH</given-names></name><name><surname>Hansen</surname> <given-names>LS</given-names></name><name><surname>Svendsen</surname> <given-names>B</given-names></name><name><surname>Christensen</surname> <given-names>M</given-names></name><name><surname>Knop</surname> <given-names>FK</given-names></name><name><surname>Hartmann</surname> <given-names>B</given-names></name><name><surname>Holst</surname> <given-names>JJ</given-names></name><name><surname>Rosenkilde</surname> <given-names>MM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Species-specific action of (Pro3)GIP - a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors</article-title><source>British Journal of Pharmacology</source><volume>173</volume><fpage>27</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1111/bph.13323</pub-id><pub-id pub-id-type="pmid">26359804</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname> <given-names>W</given-names></name><name><surname>Chen</surname> <given-names>LN</given-names></name><name><surname>Zhou</surname> <given-names>Q</given-names></name><name><surname>Zhao</surname> <given-names>LH</given-names></name><name><surname>Yang</surname> <given-names>D</given-names></name><name><surname>Zhang</surname> <given-names>H</given-names></name><name><surname>Cong</surname> <given-names>Z</given-names></name><name><surname>Shen</surname> <given-names>DD</given-names></name><name><surname>Zhao</surname> <given-names>F</given-names></name><name><surname>Zhou</surname> <given-names>F</given-names></name><name><surname>Cai</surname> <given-names>X</given-names></name><name><surname>Chen</surname> <given-names>Y</given-names></name><name><surname>Zhou</surname> <given-names>Y</given-names></name><name><surname>Gadgaard</surname> <given-names>S</given-names></name><name><surname>van der Velden</surname> <given-names>WJC</given-names></name><name><surname>Zhao</surname> <given-names>S</given-names></name><name><surname>Jiang</surname> <given-names>Y</given-names></name><name><surname>Rosenkilde</surname> <given-names>MM</given-names></name><name><surname>Xu</surname> <given-names>HE</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Wang</surname> <given-names>MW</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A unique hormonal recognition feature of the human glucagon-like peptide-2 receptor</article-title><source>Cell Research</source><volume>30</volume><fpage>1098</fpage><lpage>1108</lpage><pub-id pub-id-type="doi">10.1038/s41422-020-00442-0</pub-id><pub-id pub-id-type="pmid">33239759</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Song</surname> <given-names>X</given-names></name><name><surname>Zhang</surname> <given-names>D</given-names></name><name><surname>Chen</surname> <given-names>X</given-names></name><name><surname>Li</surname> <given-names>X</given-names></name><name><surname>Sun</surname> <given-names>Y</given-names></name><name><surname>Li</surname> <given-names>C</given-names></name><name><surname>Song</surname> <given-names>Y</given-names></name><name><surname>Ding</surname> <given-names>Y</given-names></name><name><surname>Ren</surname> <given-names>R</given-names></name><name><surname>Harrington</surname> <given-names>EH</given-names></name><name><surname>Hu</surname> <given-names>LA</given-names></name><name><surname>Zhong</surname> <given-names>W</given-names></name><name><surname>Xu</surname> <given-names>C</given-names></name><name><surname>Huang</surname> <given-names>X</given-names></name><name><surname>Wang</surname> <given-names>HW</given-names></name><name><surname>Ma</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Cryo-EM structures of PAC1 receptor reveal ligand binding mechanism</article-title><source>Cell Research</source><volume>30</volume><fpage>436</fpage><lpage>445</lpage><pub-id pub-id-type="doi">10.1038/s41422-020-0280-2</pub-id><pub-id pub-id-type="pmid">32047270</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wootten</surname> <given-names>D</given-names></name><name><surname>Simms</surname> <given-names>J</given-names></name><name><surname>Miller</surname> <given-names>LJ</given-names></name><name><surname>Christopoulos</surname> <given-names>A</given-names></name><name><surname>Sexton</surname> <given-names>PM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Polar transmembrane interactions drive formation of ligand-specific and signal pathway-biased family B G protein-coupled receptor conformations</article-title><source>PNAS</source><volume>110</volume><fpage>5211</fpage><lpage>5216</lpage><pub-id pub-id-type="doi">10.1073/pnas.1221585110</pub-id><pub-id pub-id-type="pmid">23479653</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname> <given-names>EL</given-names></name><name><surname>Cheng</surname> <given-names>X</given-names></name><name><surname>Jo</surname> <given-names>S</given-names></name><name><surname>Rui</surname> <given-names>H</given-names></name><name><surname>Song</surname> <given-names>KC</given-names></name><name><surname>Dávila-Contreras</surname> <given-names>EM</given-names></name><name><surname>Qi</surname> <given-names>Y</given-names></name><name><surname>Lee</surname> <given-names>J</given-names></name><name><surname>Monje-Galvan</surname> <given-names>V</given-names></name><name><surname>Venable</surname> <given-names>RM</given-names></name><name><surname>Klauda</surname> <given-names>JB</given-names></name><name><surname>Im</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>CHARMM-GUI Membrane Builder toward realistic biological membrane simulations</article-title><source>Journal of Computational Chemistry</source><volume>35</volume><fpage>1997</fpage><lpage>2004</lpage><pub-id pub-id-type="doi">10.1002/jcc.23702</pub-id><pub-id pub-id-type="pmid">25130509</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname> <given-names>L</given-names></name><name><surname>Yang</surname> <given-names>D</given-names></name><name><surname>de Graaf</surname> <given-names>C</given-names></name><name><surname>Moeller</surname> <given-names>A</given-names></name><name><surname>West</surname> <given-names>GM</given-names></name><name><surname>Dharmarajan</surname> <given-names>V</given-names></name><name><surname>Wang</surname> <given-names>C</given-names></name><name><surname>Siu</surname> <given-names>FY</given-names></name><name><surname>Song</surname> <given-names>G</given-names></name><name><surname>Reedtz-Runge</surname> <given-names>S</given-names></name><name><surname>Pascal</surname> <given-names>BD</given-names></name><name><surname>Wu</surname> <given-names>B</given-names></name><name><surname>Potter</surname> <given-names>CS</given-names></name><name><surname>Zhou</surname> <given-names>H</given-names></name><name><surname>Griffin</surname> <given-names>PR</given-names></name><name><surname>Carragher</surname> <given-names>B</given-names></name><name><surname>Yang</surname> <given-names>H</given-names></name><name><surname>Wang</surname> <given-names>MW</given-names></name><name><surname>Stevens</surname> <given-names>RC</given-names></name><name><surname>Jiang</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Conformational states of the full-length glucagon receptor</article-title><source>Nature Communications</source><volume>6</volume><elocation-id>7859</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms8859</pub-id><pub-id pub-id-type="pmid">26227798</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname> <given-names>D</given-names></name><name><surname>Zhou</surname> <given-names>Q</given-names></name><name><surname>Labroska</surname> <given-names>V</given-names></name><name><surname>Qin</surname> <given-names>S</given-names></name><name><surname>Darbalaei</surname> <given-names>S</given-names></name><name><surname>Wu</surname> <given-names>Y</given-names></name><name><surname>Yuliantie</surname> <given-names>E</given-names></name><name><surname>Xie</surname> <given-names>L</given-names></name><name><surname>Tao</surname> <given-names>H</given-names></name><name><surname>Cheng</surname> <given-names>J</given-names></name><name><surname>Liu</surname> <given-names>Q</given-names></name><name><surname>Zhao</surname> <given-names>S</given-names></name><name><surname>Shui</surname> <given-names>W</given-names></name><name><surname>Jiang</surname> <given-names>Y</given-names></name><name><surname>Wang</surname> <given-names>MW</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>G protein-coupled receptors: structure- and function-based drug discovery</article-title><source>Signal Transduction and Targeted Therapy</source><volume>6</volume><elocation-id>7</elocation-id><pub-id pub-id-type="doi">10.1038/s41392-020-00435-w</pub-id><pub-id pub-id-type="pmid">33414387</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yaqub</surname> <given-names>T</given-names></name><name><surname>Tikhonova</surname> <given-names>IG</given-names></name><name><surname>Lättig</surname> <given-names>J</given-names></name><name><surname>Magnan</surname> <given-names>R</given-names></name><name><surname>Laval</surname> <given-names>M</given-names></name><name><surname>Escrieut</surname> <given-names>C</given-names></name><name><surname>Boulègue</surname> <given-names>C</given-names></name><name><surname>Hewage</surname> <given-names>C</given-names></name><name><surname>Fourmy</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Identification of determinants of glucose-dependent insulinotropic polypeptide receptor that interact with N-terminal biologically active region of the natural ligand</article-title><source>Molecular Pharmacology</source><volume>77</volume><fpage>547</fpage><lpage>558</lpage><pub-id pub-id-type="doi">10.1124/mol.109.060111</pub-id><pub-id pub-id-type="pmid">20061446</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuliantie</surname> <given-names>E</given-names></name><name><surname>Darbalaei</surname> <given-names>S</given-names></name><name><surname>Dai</surname> <given-names>A</given-names></name><name><surname>Zhao</surname> <given-names>P</given-names></name><name><surname>Yang</surname> <given-names>D</given-names></name><name><surname>Sexton</surname> <given-names>PM</given-names></name><name><surname>Wang</surname> <given-names>MW</given-names></name><name><surname>Wootten</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Pharmacological characterization of mono-, dual- and tri-peptidic agonists at GIP and GLP-1 receptors</article-title><source>Biochemical Pharmacology</source><volume>177</volume><elocation-id>114001</elocation-id><pub-id pub-id-type="doi">10.1016/j.bcp.2020.114001</pub-id><pub-id pub-id-type="pmid">32360365</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Sun</surname> <given-names>B</given-names></name><name><surname>Feng</surname> <given-names>D</given-names></name><name><surname>Hu</surname> <given-names>H</given-names></name><name><surname>Chu</surname> <given-names>M</given-names></name><name><surname>Qu</surname> <given-names>Q</given-names></name><name><surname>Tarrasch</surname> <given-names>JT</given-names></name><name><surname>Li</surname> <given-names>S</given-names></name><name><surname>Sun Kobilka</surname> <given-names>T</given-names></name><name><surname>Kobilka</surname> <given-names>BK</given-names></name><name><surname>Skiniotis</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2017">2017a</year><article-title>Cryo-EM structure of the activated GLP-1 receptor in complex with a G protein</article-title><source>Nature</source><volume>546</volume><fpage>248</fpage><lpage>253</lpage><pub-id pub-id-type="doi">10.1038/nature22394</pub-id><pub-id pub-id-type="pmid">28538729</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>H</given-names></name><name><surname>Qiao</surname> <given-names>A</given-names></name><name><surname>Yang</surname> <given-names>D</given-names></name><name><surname>Yang</surname> <given-names>L</given-names></name><name><surname>Dai</surname> <given-names>A</given-names></name><name><surname>de Graaf</surname> <given-names>C</given-names></name><name><surname>Reedtz-Runge</surname> <given-names>S</given-names></name><name><surname>Dharmarajan</surname> <given-names>V</given-names></name><name><surname>Zhang</surname> <given-names>H</given-names></name><name><surname>Han</surname> <given-names>GW</given-names></name><name><surname>Grant</surname> <given-names>TD</given-names></name><name><surname>Sierra</surname> <given-names>RG</given-names></name><name><surname>Weierstall</surname> <given-names>U</given-names></name><name><surname>Nelson</surname> <given-names>G</given-names></name><name><surname>Liu</surname> <given-names>W</given-names></name><name><surname>Wu</surname> <given-names>Y</given-names></name><name><surname>Ma</surname> <given-names>L</given-names></name><name><surname>Cai</surname> <given-names>X</given-names></name><name><surname>Lin</surname> <given-names>G</given-names></name><name><surname>Wu</surname> <given-names>X</given-names></name><name><surname>Geng</surname> <given-names>Z</given-names></name><name><surname>Dong</surname> <given-names>Y</given-names></name><name><surname>Song</surname> <given-names>G</given-names></name><name><surname>Griffin</surname> <given-names>PR</given-names></name><name><surname>Lau</surname> <given-names>J</given-names></name><name><surname>Cherezov</surname> <given-names>V</given-names></name><name><surname>Yang</surname> <given-names>H</given-names></name><name><surname>Hanson</surname> <given-names>MA</given-names></name><name><surname>Stevens</surname> <given-names>RC</given-names></name><name><surname>Zhao</surname> <given-names>Q</given-names></name><name><surname>Jiang</surname> <given-names>H</given-names></name><name><surname>Wang</surname> <given-names>MW</given-names></name><name><surname>Wu</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2017">2017b</year><article-title>Structure of the full-length glucagon class B G-protein-coupled receptor</article-title><source>Nature</source><volume>546</volume><fpage>259</fpage><lpage>264</lpage><pub-id pub-id-type="doi">10.1038/nature22363</pub-id><pub-id pub-id-type="pmid">28514451</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>H</given-names></name><name><surname>Qiao</surname> <given-names>A</given-names></name><name><surname>Yang</surname> <given-names>L</given-names></name><name><surname>Van Eps</surname> <given-names>N</given-names></name><name><surname>Frederiksen</surname> <given-names>KS</given-names></name><name><surname>Yang</surname> <given-names>D</given-names></name><name><surname>Dai</surname> <given-names>A</given-names></name><name><surname>Cai</surname> <given-names>X</given-names></name><name><surname>Zhang</surname> <given-names>H</given-names></name><name><surname>Yi</surname> <given-names>C</given-names></name><name><surname>Cao</surname> <given-names>C</given-names></name><name><surname>He</surname> <given-names>L</given-names></name><name><surname>Yang</surname> <given-names>H</given-names></name><name><surname>Lau</surname> <given-names>J</given-names></name><name><surname>Ernst</surname> <given-names>OP</given-names></name><name><surname>Hanson</surname> <given-names>MA</given-names></name><name><surname>Stevens</surname> <given-names>RC</given-names></name><name><surname>Wang</surname> <given-names>MW</given-names></name><name><surname>Reedtz-Runge</surname> <given-names>S</given-names></name><name><surname>Jiang</surname> <given-names>H</given-names></name><name><surname>Zhao</surname> <given-names>Q</given-names></name><name><surname>Wu</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Structure of the glucagon receptor in complex with a glucagon analogue</article-title><source>Nature</source><volume>553</volume><fpage>106</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1038/nature25153</pub-id><pub-id pub-id-type="pmid">29300013</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>X</given-names></name><name><surname>Belousoff</surname> <given-names>MJ</given-names></name><name><surname>Zhao</surname> <given-names>P</given-names></name><name><surname>Kooistra</surname> <given-names>AJ</given-names></name><name><surname>Truong</surname> <given-names>TT</given-names></name><name><surname>Ang</surname> <given-names>SY</given-names></name><name><surname>Underwood</surname> <given-names>CR</given-names></name><name><surname>Egebjerg</surname> <given-names>T</given-names></name><name><surname>Šenel</surname> <given-names>P</given-names></name><name><surname>Stewart</surname> <given-names>GD</given-names></name><name><surname>Liang</surname> <given-names>Y-L</given-names></name><name><surname>Glukhova</surname> <given-names>A</given-names></name><name><surname>Venugopal</surname> <given-names>H</given-names></name><name><surname>Christopoulos</surname> <given-names>A</given-names></name><name><surname>Furness</surname> <given-names>SGB</given-names></name><name><surname>Miller</surname> <given-names>LJ</given-names></name><name><surname>Reedtz-Runge</surname> <given-names>S</given-names></name><name><surname>Langmead</surname> <given-names>CJ</given-names></name><name><surname>Gloriam</surname> <given-names>DE</given-names></name><name><surname>Danev</surname> <given-names>R</given-names></name><name><surname>Sexton</surname> <given-names>PM</given-names></name><name><surname>Wootten</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Differential GLP-1R Binding and Activation by Peptide and Non-peptide Agonists</article-title><source>Molecular Cell</source><volume>80</volume><fpage>e487</fpage><lpage>e500</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2020.09.020</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname> <given-names>LH</given-names></name><name><surname>Ma</surname> <given-names>S</given-names></name><name><surname>Sutkeviciute</surname> <given-names>I</given-names></name><name><surname>Shen</surname> <given-names>DD</given-names></name><name><surname>Zhou</surname> <given-names>XE</given-names></name><name><surname>de Waal</surname> <given-names>PW</given-names></name><name><surname>Li</surname> <given-names>CY</given-names></name><name><surname>Kang</surname> <given-names>Y</given-names></name><name><surname>Clark</surname> <given-names>LJ</given-names></name><name><surname>Jean-Alphonse</surname> <given-names>FG</given-names></name><name><surname>White</surname> <given-names>AD</given-names></name><name><surname>Yang</surname> <given-names>D</given-names></name><name><surname>Dai</surname> <given-names>A</given-names></name><name><surname>Cai</surname> <given-names>X</given-names></name><name><surname>Chen</surname> <given-names>J</given-names></name><name><surname>Li</surname> <given-names>C</given-names></name><name><surname>Jiang</surname> <given-names>Y</given-names></name><name><surname>Watanabe</surname> <given-names>T</given-names></name><name><surname>Gardella</surname> <given-names>TJ</given-names></name><name><surname>Melcher</surname> <given-names>K</given-names></name><name><surname>Wang</surname> <given-names>MW</given-names></name><name><surname>Vilardaga</surname> <given-names>JP</given-names></name><name><surname>Xu</surname> <given-names>HE</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Structure and dynamics of the active human parathyroid hormone receptor-1</article-title><source>Science</source><volume>364</volume><fpage>148</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1126/science.aav7942</pub-id><pub-id pub-id-type="pmid">30975883</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname> <given-names>F</given-names></name><name><surname>Zhang</surname> <given-names>H</given-names></name><name><surname>Cong</surname> <given-names>Z</given-names></name><name><surname>Zhao</surname> <given-names>LH</given-names></name><name><surname>Zhou</surname> <given-names>Q</given-names></name><name><surname>Mao</surname> <given-names>C</given-names></name><name><surname>Cheng</surname> <given-names>X</given-names></name><name><surname>Shen</surname> <given-names>DD</given-names></name><name><surname>Cai</surname> <given-names>X</given-names></name><name><surname>Ma</surname> <given-names>C</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Dai</surname> <given-names>A</given-names></name><name><surname>Zhou</surname> <given-names>Y</given-names></name><name><surname>Sun</surname> <given-names>W</given-names></name><name><surname>Zhao</surname> <given-names>F</given-names></name><name><surname>Zhao</surname> <given-names>S</given-names></name><name><surname>Jiang</surname> <given-names>H</given-names></name><name><surname>Jiang</surname> <given-names>Y</given-names></name><name><surname>Yang</surname> <given-names>D</given-names></name><name><surname>Eric Xu</surname> <given-names>H</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Wang</surname> <given-names>MW</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Structural basis for activation of the growth hormone-releasing hormone receptor</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>5205</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-18945-0</pub-id><pub-id pub-id-type="pmid">33060564</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.68719.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Drew</surname><given-names>David</given-names></name><role>Reviewing Editor</role><aff><institution>Stockholm University</institution><country>Sweden</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Shukla</surname><given-names>Arun</given-names> </name><role>Reviewer</role><aff><institution/></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>The paper describes the cryo-EM structure of the class B receptor glucose-dependent insulinotropic polypeptide (GIP)-receptor in complex with the Gs heterotrimer and the 42 amino acid hormone GIP, which is an incretin and stimulates insulin secretion in a glucose-dependent manner. The complex structure provides important insights into ligand recognition, receptor activation and transducer coupling. In particular, the interaction of GIP with GIPR reveals previously unresolved details of how the hormone is recognized by the receptor, and the structural differences compared to the previously obtained structure of the incretin glucagon-like peptide 1-Gs complex.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Structural insights into hormone recognition by the human glucose-dependent insulinotropic polypeptide receptor&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 2 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Volker Dötsch as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Arun Shukla (Reviewer #2).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1) As the authors have pointed out that map density for some of the ECD was poor. Currently the structure for the ECD has been modelled from previously determined structures of closely related GLP/GCGR. However, after inspection in Coot these models actually do not fit part of the ECD density that is present, indicating some differences here. Furthermore, detailed interactions are discussed in the paper between the ECD and GIP peptide that cannot be validated by the present maps as the location of some the side-chains are ambiguous. It is essential that the authors either I) improve the current cryo EM maps and/or re-model the structure to more faithfully fit the map density. In this regard, some further experimental and/or computational support might be needed if it is not possible to improve the map quality. The text should be appropriately adjusted.</p><p>2) It would be helpful to clarify how significant is the ambiguity in the C-terminal end of the modelled GIP peptide? This raises an important point since only 30 out of the 42 GIP residues could be modelled. Is 30aa of the GIP peptide enough for full activation? The GLP-1 is only 30 or 31 amino acids long. Is it known why the GIP peptide is longer as is the length of this peptide important for specificity, if so, then the poorly modelled region at the end of the peptide might be significant and should be clarified.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.68719.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) As the authors have pointed out that map density for some of the ECD was poor. Currently the structure for the ECD has been modelled from previously determined structures of closely related GLP/GCGR. However, after inspection in Coot these models actually do not fit part of the ECD density that is present, indicating some7 differences here. Furthermore, detailed interactions are discussed in the paper between the ECD and GIP peptide that cannot be validated by the present maps as the location of some the side-chains are ambiguous. It is essential that the authors either I) improve the current cryo EM maps and/or re-model the structure to more faithfully fit the map density. In this regard, some further experimental and/or computational support might be needed if it is not possible to improve the map quality. The text should be appropriately adjusted.</p></disp-quote><p>We appreciate the reviewers’ insightful comments. Compared to the core structure, the density of ECD is relatively poor owning to its intrinsic flexibility, which is a general feature in most reported class B1 GPCR–G<sub>s</sub> complex structures. Based on an X-ray crystal structure of GIPR ECD (PDB code: 2QKH), the initial ECD model was built and then docked into the cryo-EM density with necessary modifications, where the ECD model may not be entirely fitted to the density in several regions.</p><p>To this point, we have gone through the model and adjusted several regions of the ECD to better fit the map density. The loop residues 104 through 111 in the ECD are omitted due to poor densities. We further refined the model with the rosetta refinement program (phenix.rosetta_refine) to improve the protein geometry and rotamer assignments, especially for those residues in the ECD region. These efforts have significantly improved the quality of our ECD model.</p><p>The descriptions of interactions between the ECD and GIP have thus been revised accordingly reflecting our mutagenesis data (Figure 2D) showing mutations in the intact or truncated ECDs greatly reduced the potency of GIP. “The C-terminal half of GIP was clasped by the GIPR ECD, closely resembling the crystal structure of GIP–GIPR ECD (PDB code: 2QKH) (<italic>21</italic>). Consistent with the interaction patterns observed in other class B1 GPCRs (14-17), Specifically, three adjacent amino acids (H18<sup>P</sup>, Q19<sup>P</sup> and Q20<sup>P</sup>) form multiple hydrogen bonds with the side-chains of Q30 and Y36 at the N-terminal α-helix of ECD, as well as N120 and E122 at the hinge region between ECD and TM1. The hydrophobic residues of GIP (F22<sup>P</sup>, V23<sup>P</sup>, L26<sup>P</sup> and L27<sup>P</sup>) in the C-terminal half of GIP occupy a complementary binding groove of the GIPR ECD, consisting of a series of hydrophobic residues (L35, Y36, W39, M67, Y68, Y87, L88, P89 and W90). Alanine substitutions in W39, D66 and Y68 significantly reduced the potency of GIP (Figure 2D). Besides, several polar contacts including H18<sup>P</sup>-Y36 and Q20<sup>P</sup>-N124 were observed.”</p><disp-quote content-type="editor-comment"><p>2) It would be helpful to clarify how significant is the ambiguity in the C-terminal end of the modelled GIP peptide? This raises an important point since only 30 out of the 42 GIP residues could be modelled. Is 30aa of the GIP peptide enough for full activation? The GLP-1 is only 30 or 31 amino acids long. Is it known why the GIP peptide is longer as is the length of this peptide important for specificity, if so, then the poorly modelled region at the end of the peptide might be significant and should be clarified.</p></disp-quote><p>We thank the reviewers for the comments. GIP is initially produced as a 153-amino acid pro-hormone that is processed to become GIP(1-42) and GIP(1-30)NH<sub>2</sub>, while the former is the main active form of GIP, and the latter is also active in the circulation. According to NMR data and the crystal structure of GIPR ECD (PDB code: 2QKH), the last 12 residues of GIP(1–42) are disordered and neither bind to the ECD nor to the TMD, indicating that these residues are not of important for ligand recognition and receptor activation (PMID: 31809770). Consistently, GIP(1–42) and GIP(1–30)NH<sub>2</sub> bind with almost identical affinity (<xref ref-type="fig" rid="sa2fig1">Author response image 1</xref>) to the receptor thereby confirming the redundancy of residues Gly31 –Gln42 (PMID: 31809770, 20185691, 26572091 and 32360365, <xref ref-type="fig" rid="sa2fig2">Author response image 2</xref>).</p><fig id="sa2fig1"><label>Author response image 1.</label><caption><title>cAMP signaling profiles of GIP(1–42) and GIP(1–30)NH<sub>2</sub>.</title><p>(PMID: 31809770).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68719-resp-fig1-v2.tif"/></fig><fig id="sa2fig2"><label>Author response image 2.</label><caption><title>Pharmacological profiles of the naturally occurring GIPR agonists, GIP(1–42) and GIP(1–30)NH<sub>2</sub>.</title><p>(A) Competition of <sup>125</sup>I-GIP(1-42) binding to GIPR by GIP analogues. Binding affinity data are expressed as a percentage of measured bound <italic>vs.</italic> bound in the absence of peptide, each corrected for non-specific binding (measured in the presence of 1 μM of GIP(1-42) or GLP-1(7-36)NH<sub>2</sub>). (B) Gα<sub>s</sub> activation in GIPR expressing cells by GIP analogues. Gα<sub>s</sub> activation assay was performed in HEK293A cells transiently transfected with either GIPR or GLP-1R. (C) cAMP accumulation at GIPR by GIP analogues. The assay was performed in HEK293 cells stably expressing GIPR or GLP-1R. Measurement was converted to absolute cAMP levels using a standard curve and then normalized to the maximal response of the cognate ligands for each receptor. (D) β-arrestin2 (β-arr2) recruitment to GIPR by GIP analogues. β-arrestin recruitment assay was performed in HEK293T cells transiently transfected with either Rluc8 tagged GIPR and Venus tagged β-arrestin 2. Data of at least four independent experiments are fitted to nonlinear regression three-parameter logistic curves. All values are means ± S.E.M. (PMID: 32360365).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68719-resp-fig2-v2.tif"/></fig></body></sub-article></article>